Compound and peptide patents
111 grouped patent records connect claimed inventions with the molecules and preparations they actually describe. The collection adds historical molecular patents, later uses and recent delivery systems.
Reported findings are now shown alongside each claim summary. 108 records have numerical or narrative outcomes; one disclosure has no measured outcomes, and two original index entries lack readable experimental text. Open each source review for all extracted comparisons, timing and limitations.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Search method, family grouping and legal-status limits
Names, aliases and Russian names were searched across all 124 current compound and peptide cards, followed by sequence, chemical-name, inventor and citation searches where useful. The GHK family was also checked at derivative level. Selected original publications were read through Google Patents; metadata, claims and relevant descriptions inform these summaries.
One representative publication is listed per indexed family. National filings, translations, corrected publications and application/grant versions are linked where the accessed family record identifies them. This grouping does not imply identical claims in every jurisdiction. Different families concerning the same compound remain separate.
Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
This is a source-based research collection, not an exhaustive patentability, validity or freedom-to-operate search. An absent match means no sufficiently verified match was added in this review. Experimental examples have not received a complete methodological audit. Clinical findings remain in the study library.
New filings and identity checks
- Historical GHK, 2011–2012: thermal-pain response, GHK plus Dalargin for early bone repair, and GHK plus Thymogen for wound-area healing. Results remain preclinical.
- Cortexin, 2026: a pending rectal-formulation application, with no clinical approval inferred.
- Modified peptide analogues, 2026: acetylated and arginine-extended GHK, Epitalon, Semax, Selank and Cortagen are different molecules from their parents.
- GHK-R4: the granted US claim specifically requires palmitoylation and four arginines.
- Respiratory peptide identity: AEDL Bronchogen must not be assigned to EDG Chonluten from a mismatched secondary citation.
- Cartilage complex: the corrected C9 publication resolves mismatched ovarian claim text in the C1 record.
- Bestim: a historical L/L-versus-D/L stereochemistry conflict remains unresolved.
111 of 111 grouped patent records
2026 European publication: modified GHK, Epitalon, Semax, Selank and Cortagen analogues
Reported findings
The disclosure reports cell-growth, telomerase-related and stability findings for chemically modified peptides, with several ambiguities in reporting.
- GHK-related long-term keratinocyte assay
- Reported cell-number multiples versus control: GHK 260-fold, GHK-Cu 320-fold, Ac-GHK-Arg-NH2 360-foldAs stated in the patent; assay normalization and duration are insufficiently clear for clinical interpretation
- Epithalon-related laboratory summary
- 41.2% for modified peptide versus 33.3% for parentThe text combines telomerase activity and telomere elongation rather than clearly separating the endpoints
Modified analogue. The family claims chemically modified peptides, including acetylated parent sequences extended with C-terminal arginine amide; it also has a 2025 WO publication.
Ac-GHK-Arg-NH2 and the corresponding modified AEDG, Semax, Selank and Cortagen constructs are different molecules from their parents. The EP and WO publications are one family, not independent studies.
- Publication
- EP4758157A1 ↗ · 2026-06-17
- Earliest priority / filing
- 2023-08-13 / 2023-08-13
- Original applicant / assignee
- Individual
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 88092996 · family publications are related filings, not independent studies.
Original title, inventors and related publications
New peptides and use thereof
Inventors: Filip Majewski.
Related profiles: GHK-Cu & GHK family · Epitalon · Semax · Selank · Cortagen
Peptide oral-delivery application: capsule within capsule
Reported findings
The nested-capsule formulation produced higher measured plasma concentrations than two comparator preparations.
- Epithalon plasma concentration
- 430 pg/mL versus 360 and 310 pg/mL60 minutesExample 50 versus nested-capsule and mixed-capsule comparators
- Epithalon plasma concentration
- 22,300 pg/mL versus 18,600 and 3,000 pg/mL120 minutesExample 50 versus CE-3 and mixed-capsule comparator
Formulation. This 2026 European publication belongs to the same family as WO2025037993A1 and describes oral peptide-delivery compositions.
Formulation claims and examples do not establish oral bioavailability or clinical equivalence for every listed peptide; this is separate from the older EP4226918 family.
- Publication
- EP4757825A1 ↗ · 2026-06-17
- Earliest priority / filing
- 2023-08-13 / 2023-08-13
- Original applicant / assignee
- Individual
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 88092942 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Dosage form for peptide agents
Inventors: Filip Majewski.
Related profiles: Epitalon
Pal-GHK: submicron delivery particles
Reported findings
Particle-size, loading and storage observations support a delivery-system claim, without a human efficacy experiment.
- Particle size
- Suitable surfactant preparations described as D50 <0.6 µmA formulation acceptance result, not skin penetration or a clinical endpoint
- Pal-GHK co-encapsulation
- Pal-GHK and Pal-GQPR mixture reported as stably encapsulated over timeThe individual numerical storage table was not transcribed
Formulation. The 2026 application describes wax-and-oil delivery particles, with palmitoylated GHK among the illustrated peptide ingredients.
Delivery performance is distinct from clinical efficacy of the ingredient or finished cosmetic.
- Publication
- EP4724027A1 ↗ · 2026-04-15
- Earliest priority / filing
- 2023-06-09 / 2024-06-03
- Original applicant / assignee
- Sederma SA
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 87889138 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Submicron particle comprising a peptide active, preparation method and uses thereof, in particular cosmetic uses
Inventors: Alex Saunois; Renata PLATCHECK RAFFIN; Cristieli ROSSINI KOPP.
EP4724027A1 · JP2026523464A · KR20260022945A · CN121240849A · FR3149503A1 · WO2024251638A1
Related profiles: GHK-Cu & GHK family
Cerebrolysin: CADASIL lifespan-use patent
Reported findings
Cerebrolysin was associated with fewer deaths, while white-matter vacuolization did not improve.
- Mortality
- 0/14 Cerebrolysin-treated versus 5/14 (36%) vehicle-treated miceAge 12–18 monthsNo human participants
- White-matter vacuoles
- 26 ± 5 with Cerebrolysin (n=14) versus 22 ± 7 with vehicle (n=8)Histological endpointMean ± SD; no significant improvement
Use. The 2026 US grant concerns Cerebrolysin in CADASIL-related lifespan applications and includes genetic mouse-model support.
Animal survival and a granted use claim do not demonstrate longer human lifespan, general longevity benefit or efficacy across all stroke populations.
- Publication
- US12589118B2 ↗ · 2026-03-31
- Earliest priority / filing
- 2017-08-28 / 2018-08-28
- Original applicant / assignee
- Ever Nuero Pharma GmbH
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 59745228 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation
Inventors: Stefan Winter; Herbert Mössler.
US12589118B2 · EP3449931B1 · JP7281450B2 · KR102676274B1 · CN111050780B · AU2018326339A1 · CA3073991A1 · EA202090108A1 · ES2767070T3 · HRP20200031T1 · MX2020002267A · PH12020500376A1 · PL3449931T3 · UA129400C2 · WO2019042983A1
Related profiles: Cerebrolysin
Pal-GHK: hydrogel delivery application
Reported findings
The hydrogel produced a larger upper-skin mass-spectrometry signal and lower residual peptide in the removed hydrogel.
- Upper-skin ion-signal AUC
- 12,114.5 hydrogel versus 1,928.4 reference formulation; reported as greater than sixfold2-hour Franz-cell experimentAnalytical imaging signal; not blood exposure or clinical response
- Residual hydrogel peptide
- Approximately 10% detectable compared with unused hydrogel, across 9 pieces2 hoursThe inventor interprets this as >90% delivery; loss from the hydrogel is not a complete mass-balance proof of skin absorption
Formulation. A 2026 hydrogel-composition application includes Pal-GHK in a dependent claim and delivery examples.
Skin-delivery experiments do not demonstrate human anti-aging benefit; the claimed composition is not a patent on all GHK-Cu products.
- Publication
- WO2026046854A1 ↗ · 2026-03-05
- Earliest priority / filing
- 2024-08-30 / 2025-08-22
- Original applicant / assignee
- Boots Co PLC
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 92633954 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide containing hydrogel compositions
Inventors: Mark Johnson; Samantha Williams; Mark O'MAHONY; Michael Bell.
Related profiles: GHK-Cu & GHK family
Cortexin: rectal formulation application
Reported findings
Some neurological and locomotor outcomes improved, but a motor-coordination endpoint remained statistically neutral.
- Neurological severity, second series
- Median mNSS 6 (2–7.25) with placebo versus 0 in treated groupsInjured rats; both formulations described as improved
- Horizontal locomotion, second series
- Median sectors crossed: 21.5 placebo, 34.5 rectal, 45.5 injectedIntact group: 56; not a human performance measure
Formulation. The 2026 international application describes suppositories containing a cerebral-cortex polypeptide complex.
A pending application does not establish an approved route, comparative clinical effectiveness or interchangeability with injected Cortexin.
- Publication
- WO2026043399A1 ↗ · 2026-02-26
- Earliest priority / filing
- 2024-08-23 / 2025-08-21
- Original applicant / assignee
- Geropharm
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 98865393 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Cortexin rectal suppositories
Inventors: Ilya Alekseevich LUGOVIK; Dmitrij Valentinovich DEMCHENKO; Petr Petrovich Rodionov.
Related profiles: Cortexin
AHK-Cu: acetate crystal-form application
Reported findings
The application reports high-purity crystal preparations and lower moisture/stability problems than the amorphous reference.
- Selected crystal example
- HPLC purity 99.6%; isolated yield 64.4%An analytical manufacturing result, not a biological response
- Other crystal preparations
- Examples report 99.1% purity with yields of 72.1% and 65.2%; another reports 98.1% purity and 88.2% yieldManufacturing conditions differ; these are not replicate clinical measurements
Formulation. This 2025 Chinese application concerns a particular AHK-Cu acetate crystal form and its preparation.
Solid-form characterization and manufacture do not establish clinical hair-growth efficacy; AHK and GHK are different sequences.
- Publication
- CN120965804A ↗ · 2025-11-18
- Earliest priority / filing
- 2024-05-17 / 2024-05-17
- Original applicant / assignee
- Shenzhen Readline Biotechnology Co ltd
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 97653072 · family publications are related filings, not independent studies.
Original title, inventors and related publications
A crystalline compound of AHK-Cu acetate and its preparation method
Inventors: 方郑; 戴柱; 张炜; 王斌; 吕梦瑶; 于铁妹; 潘俊锋; 刘建.
Related profiles: GHK-Cu & GHK family
Bromantane: maladaptive learning and stimulant-use hypotheses
Reported findings
The patent describes short-term self-reported reductions in stimulant use and cravings, not a controlled addiction-treatment result.
- Stimulant-use observations
- Participants reporting cocaine or amphetamine dependence reportedly stopped on the first intervention day and maintained abstinence for approximately 3 weeksFour-week observationSelf-report; no biochemical confirmation or control group established
- Opioid-use observation
- One opioid-dependent participant reported reduced use and cravingsQualitative individual observation; no numerical reduction given
Use. This 2025 publication proposes bromantane in methods addressing maladaptive learning and stimulant-use disorders.
The indexed WO status is member-specific; this filing is not a completed clinical addiction trial and does not establish the status of every national family member.
- Publication
- WO2025040956A2 ↗ · 2025-02-27
- Earliest priority / filing
- 2023-08-09 / 2024-08-10
- Original applicant / assignee
- Individual
- Indexed status
- Ceased · checked 2026-11-06
- Patent family
- 94731432 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Drug to treat stimulant addiction
Inventors: Davin RAUTIOLA.
WO2025040956A2 · US20260191802A1 · EP4734971A2 · KR20260049775A · CN121729226A · AU2024326725A1
Related profiles: Bromantane
Selank: 2025 pancreatic-injury patent
Narrative findings; numerical extraction incomplete
The patent describes less pancreatic inflammation and structural damage during Selank treatment.
- Histology
- Purulent inflammatory changes were absent in the treated tissue examples; stromal inflammatory proliferation and islet sclerosis were reducedRat toxic-injury models; numerical histological scores not transcribed
- Islet preservation
- Islet-area preservation described with both administration routesThe narrative describes similar effects; no formal equivalence analysis established
Use. The patent proposes Selank in toxic pancreatic-injury research with animal-model support.
Toxic injury in rats does not establish treatment of diabetes, autoimmune pancreatitis or human pancreatic disease.
- Publication
- RU2833679C1 ↗ · 2025-01-28
- Earliest priority / filing
- Not established / 2023-09-15
- Original applicant / assignee
- Акционерное общество "Инновационный научно-производственный центр "Пептоген"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Use of thr-lys-pro-arg-pro-gly-pro peptide for protection of insular pancreas and exocrine section thereof from toxic destructive effects
Inventors: Николай Алексеевич Смирнов; Александр Леонидович Хохлов; Елена Игоревна Самарина; Сергей Владимирович Куликов; Владимир Николаевич Федоров; Татьяна Алимовна Зубова.
Related profiles: Selank
Slavinorm: critical limb-ischemia method
Reported findings
Both cases reportedly improved after combined care, but bypass thrombosis or loss of bypass function also occurred during follow-up.
- Case 1: walking and ankle–brachial index
- Walking distance increased from 10 m to 700 m; affected-leg ABI increased from 0.32 to 0.705 monthsBefore versus after surgery and multidrug care
- Case 2: walking and ankle–brachial index
- Walking distance reported as 800 m; affected-leg ABI increased from 0.27 to 0.804 monthsBefore versus after combined care
Use. This 2024 method patent includes Slavinorm during combined treatment of critical limb ischemia in diabetes.
The combined-care claim is not a controlled estimate of Slavinorm's independent effect and does not prove equivalence to a synthetic vascular peptide.
- Publication
- RU2827088C1 ↗ · 2024-09-23
- Earliest priority / filing
- Not established / 2024-03-20
- Original applicant / assignee
- Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for combined treatment of patients with critical ischemia of lower extremities with underlying diabetes mellitus
Inventors: Евгений Петрович Кривощеков; Владислав Павлович Компаниец; Владислав Евгеньевич Романов; Николай Александрович Лысов; Максим Вячеславович Яшков; Дмитрий Валерьевич Роднянский.
Related profiles: Vasolin / Slavinorm
Dalargin: menopausal symptoms and six-month follow-up
Reported findings
The inventor reports symptom improvement after Dalargin with persistence at six months. Pineamin and IPH GAA are background references, not treatments in this comparison.
- Reported clinical improvement
- 15/15 (100%) with Dalargin versus 5/8 (62.5%) with placeboAfter the 30-day courseBroad symptom-based outcome; no prespecified responder threshold reported
- Six-month follow-up
- All 15 Dalargin recipients reportedly retained improvement; all 8 placebo recipients returned to baseline6 monthsFollow-up completeness and independent assessment not established
Use. This 2024 patent reports a 23-woman comparison of Dalargin versus saline placebo. Pineamin is mentioned only as background, not as a tested combination.
The small unequal groups, undefined response criteria and unverified allocation and masking prevent an established treatment effect.
- Publication
- RU2821826C1 ↗ · 2024-06-26
- Earliest priority / filing
- Not established / 2024-04-13
- Original applicant / assignee
- Борис Юльевич Чебураков
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of treating climacteric syndrome in women
Inventors: Борис Юльевич Чебураков.
Related profiles: Dalargin
Pal-GHK-R4: granted US claim is narrower than the abstract
Reported findings
The modified peptides affected MMP activity and collagen at lower tested concentrations than GHK-acetate.
- MMP-2 inhibition
- GHK-R4 active at about one-tenth, Pal-GHK-R4 at about one-hundredth, the stated GHK-acetate concentrationConcentration comparison in a laboratory assay, not a clinical potency ratio
- Collagen synthesis
- GHK-R4 active at about one-fifth and Pal-GHK-R4 at about one-hundredth the GHK-acetate concentrationConcentration-dependent increases after UVB stress; no human wrinkle measurements
Modified analogue. US claim 1 requires both an N-terminal palmitoyl group and four C-terminal arginines attached to GHK.
The broader family description also discusses GHK-R4. The granted US claim must not be read as a claim to ordinary GHK, GHK-Cu or every unpalmitoylated R4 construct.
- Publication
- US11912787B2 ↗ · 2024-02-27
- Earliest priority / filing
- 2019-01-28 / 2020-01-22
- Original applicant / assignee
- Dermafirm Inc
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 71842232 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide for skin aging prevention and wrinkle reduction, and composition comprising same
Inventors: Hoon Cha; Young Il KWON; Sang Cheol Han; Jin Wook Kim; Mi Young Lee; Ga Hee HUR.
US11912787B2 · KR102203356B1 · CN113271957B · WO2020159143A1
Related profiles: GHK-Cu & GHK family
Trekrezan: defined composition and minor components
Narrative findings; numerical extraction incomplete
The disclosure claims faster dissolution and earlier clinical recovery, but does not provide a sufficiently clear completed-trial outcome table.
- Dissolution comparison
- The composition is described as dissolving faster than the reference preparationA formulation result; no transcribed dissolution curve or comparative exposure estimate
- Clinical assertion
- Improvement stated by day 3 and complete recovery by day 9, versus residual symptoms with the referenceNo verified analyzed denominator, arm-level recovery counts or uncertainty supplied
Formulation. The claims concern a specified Trekrezan-related composition, including defined minor constituents.
A composition with particular constituents is narrower than the base molecule; efficacy should not be assigned to impurities without supporting experiments.
- Publication
- RU2806642C1 ↗ · 2023-11-02
- Earliest priority / filing
- Not established / 2023-04-07
- Original applicant / assignee
- Общество с ограниченной ответственностью "Гротекс"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Adaptogenic, immunomodulating and anti-viral pharmaceutical composition of oxyethylammonium methylphenoxyacetate
Inventors: Олег Викторович Жеребцов; Ерануи Феликсовна Агаджанян; Яна Александровна Каменчук.
Related profiles: Trekrezan
Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9
Reported findings
GTS-302 reduced the composite withdrawal index while several individual signs and general activity remained unchanged.
- Composite withdrawal index
- Reported reductions of 26.9%, 41.4% and 36.5% across three tested exposuresRelative to active control; nonmonotonic dose pattern retained
- Neutral signs
- No significant changes in general motor activity, rearing, grooming or several listed withdrawal signsNot every component improved
Molecule. Corrected publication describing dimeric NT-3 peptide mimetics; proposed disease indications are not demonstrated human efficacy.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2800369C9 ↗ · 2023-10-04
- Earliest priority / filing
- Not established / 2022-04-05
- Original applicant / assignee
- Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Dimeric dipeptide mimetics of neurotrofin-3
Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Юлия Венеровна Вахитова; Полина Юрьевна Поварнина; Татьяна Алексеевна Антипова; Лариса Геннадьевна Колик; Нелля Михайловна Сазонова; Алексей Валерьевич Тарасюк; Дмитрий Михайлович Никифоров; Лиана Фанзилевна Зайнуллина; Марк Анатольевич Константинопольский; Светлана Сергеевна Ягубова; Рита Ушеровна Островская; Сергей Владимирович Николаев; Илья Олегович Логвинов.
Related profiles: NT-3 mimetics: GTS-301 & GTS-302
Pharmaceutical single dosage form for oral delivery of peptides — EP4226918A1
Reported findings
The disclosure reports higher plasma peptide concentrations for nested-capsule formulations than selected comparators.
- GHK-Cu at 60 minutes
- 350 pg/mL inventive formulation versus 320 and 150 pg/mL comparators60 minutesFormulation examples; not a clinical skin or wound outcome
- Epithalon at 60 minutes
- 360 pg/mL inventive formulation versus 310 and 50 pg/mL comparators60 minutesIndividual patent pharmacokinetic example
Formulation. Oral peptide-delivery composition, including Epitalon; listed peptide ingredients are not a demonstration of oral clinical efficacy.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- EP4226918A1 ↗ · 2023-08-16
- Earliest priority / filing
- 2022-02-15 / 2022-02-15
- Original applicant / assignee
- Individual
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 80682691 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical single dosage form for oral delivery of peptides
Inventors: Filip Majewski.
Related profiles: Epitalon · GHK-Cu & GHK family
Dalargin: nasal respiratory-infection use and formulation
Narrative findings; numerical extraction incomplete
The patent reports reduced stimulated inflammatory-cytokine production and altered innate-cell activity.
- Donor-cell cytokines
- Reduced stimulated IL-1, IL-6 and TNF-α production reportedIn-vitro experiment using cells from 20 donors; exact figure percentages not transcribed
- Animal innate-cell findings
- Increased phagocytic activity described; no detected difference between the tested routesA laboratory result, not demonstrated clinical infection recovery
Formulation. The patent concerns nasal Dalargin compositions and proposed respiratory-infection applications.
A granted formulation or use claim does not establish clinical antiviral benefit.
- Publication
- EP3556377B1 ↗ · 2021-09-08
- Earliest priority / filing
- 2018-04-18 / 2019-04-10
- Original applicant / assignee
- PVP Labs Pte Ltd
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 64328036 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Dalargin for use in the treatment of acute respiratory viral infections
Inventors: Evgeny Alexandrovich Chertorizhsky; Mikhail Vladimirovich Ovchinnikov; Aleksey Viktorovich Kleimenov.
EP3556377B1 · US11365216B2 · JP6952379B2 · KR20200132931A · CN112020367B · CA3093492C · EA037430B1 · ES2901193T3 · HRP20211906T1 · HUE056471T2 · MY206814A · PH12020551709A1 · PL3556377T3 · PT3556377T · RS62632B1 · RU2672888C1 · SG11202009591PA · WO2019202380A1 · ZA202006656B
Related profiles: Dalargin
GHK-VEP: learning and memory claim
Reported findings
GHK-VEP shortened some response measures, while several later comparisons were neutral.
- Training day 1 reaction time
- 13.0 (10.1–31.2) s with GHK-VEP versus 39.4 (20.0–69.4) s controlMedian and quartile-style ranges as reported
- Training day 2 reaction time
- 17.5 (4.6–42.0) s versus 85.8 (13.5–140.2) s controlSame table endpoint
Use. The claimed peptide is GHK-Val-Glu-Pro, investigated for effects on learning and memory.
This is GHK-VEP, not GHK-GP or GHK-Cu; the patent does not establish clinical cognitive benefit.
- Publication
- RU2743293C1 ↗ · 2021-02-16
- Earliest priority / filing
- 2020-07-06 / 2020-07-06
- Original applicant / assignee
- Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 74666249 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Use of Gly-His-Lys-Val-Glu-Pro peptide to improve learning abilty and memory.
Inventors: Игорь Иванович Бобынцев; Марина Евгеньевна Алферова; Анна Николаевна Тенькова; Андрей Евгеньевич Белых; Антон Олегович Ворвуль; Марина Геннадьевна Анфилова; Людмила Александровна Андреева; Николай Федорович Мясоедов.
Related profiles: GHK-Cu & GHK family
Bromantane and derivatives: fibrosis research
Narrative findings; numerical extraction incomplete
The renal experiment reports lower fibrosis and blood urea nitrogen with bromantane, alongside some neutral or numerical-only organ-weight comparisons.
- Kidney fibrosis and BUN
- Significant reductions versus vehicle reportedExact effect sizes and figure values were not transcribed; no patient trial
- Kidney weight
- Affected-kidney weight showed a numerical reduction; the uninjured-kidney change was described as significantNumerical change is distinguished from statistical significance
Use. The application proposes bromantane-related compounds for lung fibrosis and other organ-disease uses.
Patent experiments and proposed indications are distinct from demonstrated human treatment effects.
- Publication
- WO2020191503A1 ↗ · 2020-10-01
- Earliest priority / filing
- 2019-03-27 / 2020-03-27
- Original applicant / assignee
- Algernon Pharmaceuticals Inc
- Indexed status
- Ceased · checked 2026-11-06
- Patent family
- 72609163 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
Inventors: Mark Williams.
Related profiles: Bromantane
Pineamin: polycystic-ovary syndrome use
Reported findings
The patent reports menstrual recovery and subsequent pregnancies in two selected cases.
- Case 1: gonadotropins
- LH 14.2 → 6.6 IU/L; FSH 4.8 → 16.4 IU/LAfter 3 monthsOne 25-year-old patient; timing within the cycle is not standardized in the report
- Case 1: reproductive outcome
- Cycle restoration, corpus luteum on ultrasound and pregnancy reportedSecond month after treatmentPregnancy is an individual case outcome; no live-birth result given
Use. The method patent proposes Pineamin in a PCOS treatment context.
Patent case examples do not establish a randomized fertility effect or make the pineal extract equivalent to synthetic Epitalon.
- Publication
- RU2732688C1 ↗ · 2020-09-22
- Earliest priority / filing
- 2020-02-06 / 2020-02-06
- Original applicant / assignee
- федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет Министерства здравоохранения Российской Федерации
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 72922335 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of treating polycystic ovary syndrome with non-hormonal preparations
Inventors: Алла Николаевна Мальцева.
Related profiles: Pineamin
Selank: adjunctive chronic-dermatosis method
Reported findings
The patent reports reductions in skin-severity and psychological scores, alongside standard topical treatment.
- Psoriasis case
- PASI 13 → 1; Beck depression 12 → 5; Hamilton anxiety 17 → 7Skin findings described through day 15Single-patient before/after findings
- Eczema case
- EASI 9 → 1; Beck depression 11 → 4Skin findings described through day 16Single-patient before/after findings
Use. The filing proposes Selank alongside care for chronic dermatoses.
Concurrent care prevents simple attribution; the document also contains a dose-unit inconsistency, so no administration regimen is reproduced here.
- Publication
- RU2709534C1 ↗ · 2019-12-18
- Earliest priority / filing
- 2018-07-12 / 2018-07-12
- Original applicant / assignee
- Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России)
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 69006604 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of treating chronic dermatoses
Inventors: Луиза Афгатовна Юсупова; Евгения Владимировна Бильдюк.
Related profiles: Selank
GB-115: activating anxiolytic application
Narrative findings; numerical extraction incomplete
The clinical narrative describes reduced anxiety with improved sleep, energy and concentration.
- Illustrative course
- Improvement began toward the end of week 1; somatic/autonomic anxiety symptoms largely reduced by week 321 daysSingle selected case, not a controlled response rate
- Clinical scale narrative
- Reduced mental and autonomic anxiety symptoms reportedThe source cites before/after significance; exact values and denominators not entered
Use. The patent proposes GB-115 as an activating anxiolytic.
The granted use is not independent confirmation of all clinical anxiety or cognition claims.
- Publication
- RU2709013C1 ↗ · 2019-12-13
- Earliest priority / filing
- 2018-10-19 / 2018-10-19
- Original applicant / assignee
- Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Use of amide n-(6-phenylhexanoyl) glycyl-l-tryptophane (gb-115) as an agent having anxiolytic properties with an activating component
Inventors: Григорий Георгиевич Незнамов; Сергей Борисович Середенин; Ольга Анатольевна Дорофеева; Марианна Вячеславовна Метлина.
Related profiles: GB-115 & CCK analogues
GHK-GP: anxiolytic-use claim
Narrative findings; numerical extraction incomplete
GHK-GP showed test- and exposure-dependent anxiolytic-like behavior.
- Elevated-plus-maze behavior
- Less time in closed arms and more open-arm exploration at selected tested exposuresReported significant comparisons against saline
- Vogel conflict behavior
- More punished drinking at the highest tested exposureA different behavioral test and exposure; not a human anxiety endpoint
Use. The claims identify glycyl-histidyl-lysyl-glycyl-proline, GHK-GP, for an anxiolytic use supported by animal testing.
GHK-GP is a specific extension of GHK; rodent behavioral findings do not establish human anxiety treatment.
- Publication
- RU2705592C1 ↗ · 2019-11-11
- Earliest priority / filing
- 2019-02-26 / 2019-02-26
- Original applicant / assignee
- Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 68579458 · family publications are related filings, not independent studies.
Original title, inventors and related publications
USE OF PEPTIDE Gly-His-Lus-Gly-Pro TO ACHIEVE ANXIOLYTIC EFFECT
Inventors: Игорь Иванович Бобынцев; Марина Евгеньевна Алферова; Анна Николаевна Тенькова; Андрей Евгеньевич Белых; Антон Олегович Ворвуль; Ирина Артуровна Телегина; Юлия Александровна Музалева; Людмила Александровна Андреева; Николай Федорович Мясоедов.
Related profiles: GHK-Cu & GHK family
Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures
Reported findings
The formulation increased rod-retention time after cold stress but did not restore the intact-animal value.
- Cold-exposure motor coordination
- 24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controlsMedians and quartiles; intact animals 127.0 (100.5–183.0) s
- Sydnocarb comparator
- 6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold controlWorse retention in this test; not general clinical inferiority
Use. Later Chlodantane use claims; Bromantane appears as a comparator and must not be treated as the claimed test compound.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2704126C2 ↗ · 2019-10-24
- Earliest priority / filing
- 2016-11-28 / 2016-11-28
- Original applicant / assignee
- Российская Федерация, от имени которой выступает Министерство обороны Российской Федерации
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 62557483 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition based on chlorobenzoylaminoadamantane, which increases physical performance in high and low temperatures
Inventors: Сергей Борисович Середенин; Григорий Георгиевич Незнамов; Валерий Гаврилович Барчуков; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Любовь Николаевна Грушевская; Надежда Михайловна Зайцева; Константин Викторович Алексеев; Евгения Викторовна Блынская; Анна Сергеевна Михеева; Людмила Михайловна Гаевая; Мария Сергеевна Сергеева; Сергей Александрович Крыжановский; Иосиф Борисович Цорин; Валерий Николаевич Столярук; Марина Борисовна Вититнова.
Related profiles: Chlodantane
GHK-D-Ala: wound-repair research
Narrative findings; numerical extraction incomplete
The patent reports stimulation of wound healing, with biochemical and wound observations followed to 30 days.
- Wound healing
- A beneficial healing effect is reported in the experimental conclusionExact closure times, wound-area means and group sizes were not extracted from the image-based results
- Follow-up
- Observations included days 1, 3, 7, 10, 20 and 30These are measurement times, not numerical healing effects
Use. The filing identifies C-terminal D-alanine-modified GHK in experimental infected-wound research.
GHK-D-Ala and D-Ala-GHK are different molecules. The reported animal model does not establish human infection treatment.
- Publication
- RU2681310C1 ↗ · 2019-03-06
- Earliest priority / filing
- 2018-09-05 / 2018-09-05
- Original applicant / assignee
- Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 65632856 · family publications are related filings, not independent studies.
Original title, inventors and related publications
SKIN AND SOFT TISSUES INFECTED WOUNDS PRIMARY SURGICAL TREATMENT METHOD USING THE Gly-His-Lys-D-Ala PEPTIDE
Inventors: Камила Камильджановна Рахметова; Игорь Иванович Бобынцев; Александр Иванович Бежин; Михаил Юрьевич Смахтин; Екатерина Сергеевна Мишина; Максим Юрьевич Хорьяков.
Related profiles: GHK-Cu & GHK family
Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis
Reported findings
Some activity and REM-sleep measures improved relative to untreated desynchronization, while sleep timing remained abnormal.
- Wheel activity
- Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900Third dayDesynchronized rats
- REM-sleep duration
- Reported 1.7-fold longer than untreated desynchronization; 62.5% versus 30% exceeded the stated REM thresholdThreshold: REM duration >50% of the baseline group average
Use. Later Cyclontane use claims and experimental support; neither a grant nor a comparator establishes human efficacy.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2674342C2 ↗ · 2018-12-07
- Earliest priority / filing
- 2016-11-28 / 2016-11-28
- Original applicant / assignee
- Российская Федерация, от имени которой выступает Министерство обороны Российской Федерации
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 62557472 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition of 1-hydroxy-4-cyclohexylaminoadamantane hydrochloride and sodium salt of 4-hydroxymic acid, improving mental and physical efficiency when having desynchronosis
Inventors: Сергей Борисович Середенин; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Любовь Николаевна Грушевская; Надежда Михайловна Зайцева; Константин Викторович Алексеев; Евгения Викторовна Блынская; Анна Сергеевна Михеева; Людмила Михайловна Гаевая; Мария Сергеевна Сергеева; Татьяна Александровна Воронина; Светлана Александровна Литвинова; Инга Геннадиевна Капица; Елена Анатольевна Иванова; Татьяна Сергеевна Калинина.
Related profiles: Cyclontane
Gamma-D-Glu-L-Trp: interferon combination claim
Narrative findings; numerical extraction incomplete
Clinical examples describe symptom resolution during treatment, without a controlled patient efficacy estimate.
- Pharyngitis example
- Initial improvement followed by worsening the next day; no complaints by day 5One 27-year-old patient; the transient worsening is retained
- Respiratory-illness example
- Nasal discharge reportedly stopped and general condition improved by day 3Individual case; natural recovery and concurrent effects are not separated
Formulation. The later patent explicitly names gamma-D-glutamyl-L-tryptophan in combination with type I or III interferon.
This is a combination claim rather than a patent on standalone Bestim efficacy; it does not resolve the older L/L-versus-D/L naming conflict.
- Publication
- RU2672861C2 ↗ · 2018-11-20
- Earliest priority / filing
- 2014-10-31 / 2014-10-31
- Original applicant / assignee
- Общество с ограниченной ответственностью "Эксифарм" (ООО "Эксифарм")
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 56095723 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Composition based on interferon i or iii type and gamma-d-glutaminyl-l-tryptophan for prevention and treatment of infectious diseases and immunodeficiency conditions (options)
Inventors: Евгения Валерьевна Безрукова; Илья Владимирович Духовлинов; Александр Митрофанович Ищенко; Александр Леонидович Кадыков; Александр Александрович Колобов; Александр Владимирович Петров; Андрей Семенович Симбирцев.
Related profiles: Bestim
Phenoxyacetamide structural analogues of Chlodantane and ADK-918
Reported findings
The disclosure reports synthesis yields; it does not supply a verified clinical adaptogenic result.
- Analogue 1 recovery
- 15.1 g, 85% yieldManufacturing result for the newly claimed analogue, not Chlodantane or ADK-918
- Analogue 2 recovery
- 80% yield; melting interval 94.5–95.0°CA different new analogue; analytical characterization
Platform context. The claimed phenoxyacetamides are described as structural analogues of ADK-910 and ADK-918, rather than claims to those reference compounds themselves.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2660654C1 ↗ · 2018-07-09
- Earliest priority / filing
- 2017-06-09 / 2017-06-09
- Original applicant / assignee
- Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ)
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 62815866 · family publications are related filings, not independent studies.
Original title, inventors and related publications
N-(adamantan-2-yl)- and n-[(adamantan-1-yl)methyl]- derivatives of 2-(4-allyl-2-methoxyphenoxy)acetic acid amide, which are potential synthetic adaptogens of emergency action
Inventors: Иван Александрович Новаков; Лейла Липпаритовна Брунилина; Андрей Александрович Вернигора; Максим Борисович Навроцкий; Борис Семёнович Орлинсон; Александр Сергеевич Яблоков.
Related profiles: Chlodantane · ADK-918
GZK-111: N-phenylacetyl glyprolin derivatives
Narrative findings; numerical extraction incomplete
The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.
- Metabolic identity
- CPG formation observed during incubation with plasma and brain homogenateSupports a precursor/metabolite relationship; not a human clinical exposure estimate
- Cell-injury comparison
- Concentration-dependent neuroprotection reported for GZK-111 in the neuronal-cell modelNo quantitative cell-survival percentage independently transcribed
Molecule. The claimed class includes phenylacetylglycyl-L-proline ethyl ester, alongside other stereochemical and terminal variants.
The precursor and cyclic metabolite CPG are different molecules. A broad class is not a patent match to every glyprolin or to the similarly named GZS-411.
- Publication
- RU2646604C2 ↗ · 2018-03-06
- Earliest priority / filing
- 2016-01-12 / 2016-01-12
- Original applicant / assignee
- Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 59497169 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Novel glyprolins with nootropic, anti-hypoxic, neuroprotective and anssiylitis activity
Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Ксения Николаевна Колясникова; Елена Александровна Кузнецова; Татьяна Александровна Воронина; Милада Альнордовна Яркова; Татьяна Алексеевна Антипова; Светлана Александровна Литвинова; Николай Николаевич Золотов.
Related profiles: CPG & GZK-111 · Glyprolins & PGP hybrids
Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2
Narrative findings; numerical extraction incomplete
Experimental effects differ by candidate: some dimers were protective or antidepressant-like, while some monomers had unfavorable effects.
- BDNF-model behavior
- GSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased itDifferent molecules; the unfavorable direction is retained
- Candidate identity and viability
- Some monomeric mimetics reduced neuronal viability; dimeric results were more favorableCandidate-specific findings, not a class-wide clinical effect
Platform context. The title refers to NGF and BDNF mimetics, but the granted US claims specifically identify a Ser-Lys-based dimer. This is not a grant to every GK, GSB, GBK or GTS candidate.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- US9683014B2 ↗ · 2017-06-20
- Earliest priority / filing
- 2009-02-16 / 2014-08-15
- Original applicant / assignee
- Uchrezhdenie Rossiiskoi Akademii Meditsynskikh Nauk Nauchno-Issledovatelsky Institut Farmakologii Imeni Vvzakusova Ramn
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 42561958 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Dipeptide mimetics of NGF and BDNF neurotrophins
Inventors: Sergey Borisovich Seredenin; Alexandrovna Tatyana GUDASHEVA.
US9683014B2 · US20110312895A1 · EP2397488B1 · CN102365294B · RU2410392C2 · WO2010093284A1
Related profiles: NGF mimetics: GK & GTS series · BDNF mimetics: GSB, GBK & GTS
Ezrin-derived peptides and pharmaceutical compositions — US9682140B2
Reported findings
The modified peptide increased MAPK/ERK phosphorylation in cell cultures.
- Phospho-ERK1
- 0.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative control1 hourNormalized laboratory signal; positive TGF-β1 control 0.50 ± 0.02
- Phospho-ERK2
- 1.30 ± 0.05 versus 0.40 ± 0.01 negative control1 hourPositive TGF-β1 control 1.90 ± 0.10
Molecule. Ezrin-derived peptide and composition claims; the claimed modified sequences are not automatically identical to the parent Gepon peptide or every marketed formulation.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- US9682140B2 ↗ · 2017-06-20
- Earliest priority / filing
- 2015-06-01 / 2016-06-01
- Original applicant / assignee
- Nearmedic International Ltd
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 56117690 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Ezrin-derived peptides and pharmaceutical compositions thereof
Inventors: Rupert Holms; Ravshan Ataullakhanov; Rustam Ataullakhanov; Khachik Sayadyan.
US9682140B2 · EP3191504B1 · JP6721419B2 · KR101842978B1 · CN106188267B · AU2016203656B2 · CA2931875C · CY1120501T1 · DK3191504T3 · ES2660894T3 · GB2546439B · HRP20180560T1 · HUE038737T2 · LT3191504T · MA39421A · MD3191504T2 · ME03033B · MX377333B · PL3191504T3 · PT3191504T · RS57067B1 · SG10201604401UA · SI3191504T1 · SMT201800190T1 · WO2016193285A1 · ZA201603723B
Related profiles: Gepon & ezrin-derived peptides
GHK: COPD and emphysema use claims
Reported findings
GHK reversed aspects of emphysema-associated expression patterns in laboratory analyses and increased selected repair-associated signals.
- Expression signature
- GHK-induced changes were anti-correlated with regional emphysema severityComputational signature matching
- Lung-fibroblast confirmation
- GHK-responsive gene sets were reproduced in fibroblast culturesA cell experiment, not an improvement in patient lung function
Use. The claims concern GHK-related treatment of obstructive pulmonary disease; a dependent claim explicitly specifies GHK without copper.
The free peptide and its copper complex are not automatically interchangeable, and a grant does not establish clinical pulmonary benefit.
- Publication
- US9585930B2 ↗ · 2017-03-07
- Earliest priority / filing
- 2011-03-20 / 2012-03-20
- Original applicant / assignee
- University of British Columbia; Boston University
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 45922835 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Therapeutic agent for emphysema and COPD
Inventors: Avrum Spira; Marc Lenburg; Joshua Campbell; Dimitri Petchkovski; Darryl Andrew Knight; James Cameron Hogg; Julie Erin Zeskind Gil.
Related profiles: GHK-Cu & GHK family
GB-115: solid dosage form
Reported findings
The solid formulation produced higher measured exposure and a longer circulating profile in the reported animal comparison.
- Relative bioavailability
- 192% relative to the reference substanceA formulation-specific rat ratio; not absolute oral bioavailability or a human value
- Elimination and residence
- Half-life 44.75 minutes; mean residence time 68.32 minutes; elimination constant 0.0155/minRat pharmacokineticsParameters reported for the formulation
Formulation. The claims concern a solid pharmaceutical form of GB-115 and formulation components.
Formulation protection is distinct from proof of clinical benefit or from the base-compound discovery claim.
- Publication
- RU2602742C2 ↗ · 2016-11-20
- Earliest priority / filing
- 2013-12-13 / 2013-12-13
- Original applicant / assignee
- Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имен В.В. Закусова"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition of n-(6-phenylhexanoyl)glycyl-l-tryptophan amide in solid dosage form
Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Константин Викторович Алексеев; Любовь Николаевна Грушевская; Лариса Геннадьевна Колик; Владимир Павлович Жердев; Надежда Михайловна Зайцева; Евгения Викторовна Блынская; Ксения Геннадьевна Турчинская; Наталья Викторовна Тихонова; Людмила Михайловна Гаевая; Марк Александрович Константинопольский; Светлана Семеновна Бойко.
Related profiles: GB-115 & CCK analogues
Ventfort plus Chonsurid: dental bone-healing method
Reported findings
The Ventfort case had higher final density but slightly later reported healing, alongside a larger defect.
- Ventfort adjunct case
- 22 mm defect: healing at 6.5 months; density 211 HUOne 63-year-old patient
- Chonsurid-only example
- 14 mm defect: healing at 6 months; density 194 HUOne 64-year-old patient
Use. The patent describes branded Ventfort in a combined dental-treatment approach.
The extract brand is not interchangeable with Vasolin, Slavinorm or purified KED, and combined treatment prevents independent attribution.
- Publication
- RU2593817C2 ↗ · 2016-08-10
- Earliest priority / filing
- 2014-10-20 / 2014-10-20
- Original applicant / assignee
- Андрей Константинович Иорданишвили
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 56011738 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of accelerating process of reparative osteogenesis
Inventors: Андрей Константинович Иорданишвили; Антон Анатольевич Сериков; Дмитрий Викторович Балин; Анна Геннадьевна Слугина; Владимир Владимирович Самсонов; Борис Лаврович Макеев; Ирина Борисовна Долгова.
Related profiles: Ventfort
Pinealon plus Chonsurid: dental bone-healing method
Reported findings
The Pinealon case reports 4.5-month healing, compared with six months in a different case with a larger initial defect.
- Pinealon adjunct case
- 8 mm defect: healing at 4.5 months; density 185 HUOne 64-year-old patient
- Chonsurid-only example
- 17 mm defect: healing at 6 months; density 177 HUOne 59-year-old patient
Use. The claims describe branded Pinealon within a combined dental-treatment method.
Branded capsules and a combined-care method must not be treated as isolated EDR efficacy or an independent replication of related reports.
- Publication
- RU2589264C2 ↗ · 2016-07-10
- Earliest priority / filing
- 2014-10-20 / 2014-10-20
- Original applicant / assignee
- Андрей Константинович Иорданишвили
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 55959662 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of accelerating process of reparative osteogenesis
Inventors: Андрей Константинович Иорданишвили; Антон Анатольевич Сериков; Дмитрий Викторович Балин; Анна Геннадьевна Слугина; Владимир Владимирович Самсонов; Борис Лаврович Макеев; Светлана Константиновна Осмоловская.
Related profiles: Pinealon
Endoluten plus Chonsurid: dental bone-healing method
Reported findings
The Endoluten case had higher final density but a longer reported healing time; the examples do not demonstrate faster healing.
- Endoluten adjunct case
- 20 mm defect: healing at 6.5 months; density 206 HUOne 66-year-old patient
- Chonsurid-only example
- 17 mm defect: healing at 4 months; density 177 HUOne 65-year-old patient
Use. The patent identifies branded Endoluten in combination with Chonsurid and dental treatment.
Endoluten is not automatically Epitalon or Epithalamin; the method cannot isolate the extract's contribution.
- Publication
- RU2589265C2 ↗ · 2016-07-10
- Earliest priority / filing
- 2014-10-20 / 2014-10-20
- Original applicant / assignee
- Андрей Константинович Иорданишвили
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 55959663 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of accelerating process of reparative osteogenesis
Inventors: Андрей Константинович Иорданишвили; Антон Анатольевич Сериков; Дмитрий Викторович Балин; Анна Геннадьевна Слугина; Владимир Владимирович Самсонов; Борис Лаврович Макеев; Людмила Юрьевна Орехова.
Related profiles: Endoluten
FDES: neuroprotective aminoethanol derivative
Reported findings
The patent reports longer survival in selected acute challenge models.
- Hemic-hypoxia model
- Lifespan and survival described as 77% and 63% higher than controlThe source does not clearly distinguish relative survival change from percentage-point change
- Histotoxic-hypoxia model
- Lifespan and survival described as 42% and 38% higher than controlShort animal challenge, not a chronic disease or patient survival outcome
Molecule. This filing identifies the FDES candidate within the aminoethanol-derivative research collection.
FDES is not ADK-17; related chemical ancestry does not establish the same structure, claim coverage or clinical effects.
- Publication
- RU2588365C1 ↗ · 2016-06-27
- Earliest priority / filing
- Not established / 2015-05-19
- Original applicant / assignee
- Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России)
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Neuroprotective agent based on bis{2-[(2e)-4-hydroxy-4-oxobut-2-enoyloxy]-n,n-diethylethanamine}butandioate
Inventors: Сергей Владимирович Оковитый; Евгений Борисович Шустов; Вера Цезаревна Болотова; Ирина Александровна Титович.
Related profiles: Aminoethanol derivatives
Vesugen plus Chonsurid: dental bone-healing method
Reported findings
The Vesugen example reports earlier radiographic healing and greater regenerate density, in a different patient and defect.
- Vesugen adjunct case
- 21 mm defect: healing at 4.5 months; regenerate density 200 HUOne 65-year-old patient
- Chonsurid-only example
- 19 mm defect: healing at 6 months; regenerate density 175 HUOne 62-year-old patient
Use. The method combines branded Vesugen with Chonsurid and dental care.
This is a combination-care claim; it does not establish the independent effect of purified KED or a general bone-healing benefit.
- Publication
- RU2582976C1 ↗ · 2016-04-27
- Earliest priority / filing
- 2014-10-20 / 2014-10-20
- Original applicant / assignee
- Андрей Константинович Иорданишвили
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 55794784 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of accelerating process of reparative osteogenesis
Inventors: Андрей Константинович Иорданишвили; Антон Анатольевич Сериков; Дмитрий Викторович Балин; Анна Геннадьевна Слугина; Владимир Владимирович Самсонов; Борис Лаврович Макеев; Сергей Константинович Осмоловский.
Related profiles: Vesugen
Bemitil plus carnitine: asthenia and fatigue claims
Reported findings
The combination improved some fatigue- and depression-like behaviors, while episodic-memory testing was neutral.
- Physical-fatigue tasks
- Combination reportedly reduced fatigue in swim and rotating-rod tests at a selected tested combinationExact mean differences not transcribed; individual drugs and combinations differed
- Depression-like behavior
- Reduced stress-associated immobility reported across tested combination exposuresBehavioral proxy, not clinical depression recovery
Formulation. The filing describes ethylthiobenzimidazole hydrobromide combined with carnitine for proposed fatigue-related applications.
This is a combination, not Etomerzol and not a demonstration of Bemitil monotherapy efficacy in ME/CFS.
- Publication
- RU2578412C1 ↗ · 2016-03-27
- Earliest priority / filing
- 2014-12-02 / 2014-12-02
- Original applicant / assignee
- Общество С Ограниченной Ответственностью "Валента - Интеллект"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 55656639 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition for treating asthenia and/or chronic fatigue syndrome
Inventors: Аллан Герович Бениашвили; Маргарита Алексеевна Морозова.
RU2578412C1 · KR101942205B1 · CN107205944A · EA027170B1 · UA112719C2 · WO2016089251A1
Related profiles: Bemitil
R-phenylpiracetam: sleep-disorder application
Narrative findings; numerical extraction incomplete
Animal data concern motivation, while the human section supplies a broad ESS-improvement assertion without adequate arm-level results.
- Animal motivation
- Greater work for preferred food described, without increased freely available ordinary-food consumptionR-isomer result; not proof of reduced clinical sleepiness
- Human ESS statement
- An improvement of at least 3 points is asserted, but no baseline/endpoint means, arm counts or uncertainty are suppliedThe text describes a 36-subject, four-week study without independently verifiable completed results
Modified analogue. The application concerns the R-enantiomer of phenylpiracetam and sleep-disorder uses.
An isolated enantiomer is not the racemic Phenotropil preparation; efficacy or legal status cannot be transferred between them without evidence.
- Publication
- EP2891491A1 ↗ · 2015-07-08
- Earliest priority / filing
- 2014-01-03 / 2014-01-03
- Original applicant / assignee
- Merz Pharma GmbH and Co KGaA
- Indexed status
- Ceased · checked 2026-11-06
- Patent family
- 49916967 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Use of (r)-phenylpiracetam for the treatment of sleep disorders
Inventors: designation of the inventor has not yet been filed The.
Related profiles: Phenotropil
Vesugen: salivary-function adjunctive method
Reported findings
Both cases reported more saliva after 30 days; the Vesugen case had the larger numerical increase.
- Conventional-care case
- Saliva collected over 20 minutes: 1.6 → 2.34 mL30 daysOne 60-year-old patient
- Vesugen adjunct case
- Saliva collected over 20 minutes: 1.3 → 4.3 mL30 daysOne 65-year-old patient receiving several treatments
Use. This method describes branded Vesugen during treatment of drug-associated salivary dysfunction.
Branded tablets and concurrent treatment are not evidence for isolated KED, and patent examples may overlap clinical reports.
- Publication
- RU2554504C1 ↗ · 2015-06-27
- Earliest priority / filing
- 2014-02-20 / 2014-02-20
- Original applicant / assignee
- Андрей Константинович Иорданишвили; Валерий Валерьевич Лобейко
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 53498546 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of treating drug sialoadenopathy
Inventors: Андрей Константинович Иорданишвили; Валерий Валерьевич Лобейко.
Related profiles: Vesugen
Actovegin: diabetic neuropathy use
Reported findings
Symptom scores favored Actovegin, while some neuropathy and quality-of-life endpoints were neutral. The patent is not independent replication of the journal trial.
- Total Symptom Score: end-to-baseline change
- −5.5 ± 2.6 versus −4.7 ± 2.9; adjusted difference −0.86End of studyActovegin versus placebo
- Time-averaged vibration threshold
- Ratio 0.97During treatmentActovegin versus placebo
Use. The patent concerns a deproteinized hemoderivative and diabetic-neuropathy treatment, with clinical material in the disclosure.
Related trial publications and patent descriptions must not be counted as independent clinical replications.
- Publication
- EA021189B1 ↗ · 2015-04-30
- Earliest priority / filing
- 2008-09-29 / 2009-09-29
- Original applicant / assignee
- Такеда Австрия Гмбх
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 41345991 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for prevention and treatment of diabetic peripheral neuropathy by a deproteinised hemoderivative
Inventors: Лусине Моусесьян.
EA021189B1 · EP2340026B1 · KR20110067054A · CN102264375A · GEP20135901B · WO2010034315A1
Related profiles: Actovegin
Cyclic glutamyl-tryptophan scaffold patent
Reported findings
One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.
- Protein-antigen response
- A tested cyclic compound reportedly increased antibody titers by 74%A model-antigen experiment; not autoimmune clinical efficacy or a verified AWE18/CP-88 result
- Oral activity comparison
- Some cyclic analogues retained oral analgesic activity where comparator peptides did notDifferent neuropeptide constructs; not evidence that every cyclic immune peptide is orally effective
Platform context. The family concerns cyclic piperazine-based immunomodulatory compounds related to the chemistry discussed for CP-88 and AWE18.
The candidate codes are not an exact verified claim match here. Treat this as platform context, not proof that a particular candidate is covered or clinically effective.
- Publication
- EP2046778B1 ↗ · 2013-12-04
- Earliest priority / filing
- 2006-08-04 / 2007-08-01
- Original applicant / assignee
- Manus Pharmaceuticals Canada Ltd
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 38996830 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Multifunctional bioactive compounds
Inventors: Vladislav I. Deigin.
EP2046778B1 · US8637521B2 · JP5357022B2 · CN101511823B · AU2007280995C1 · BRPI0714616A2 · CA2659875C · EA018548B1 · MX2009001351A · WO2008014613A1
Pinealon / EDR: post-injury neurological use
Reported findings
The report describes better corrective-test performance and an EEG alpha-index change after EDR-containing treatment.
- Corrective test: characters registered
- 2,429.6 ± 105.3 after EDR-containing treatment versus 1,967.5 ± 122.4 after conventional careAfter the courseReported pre-treatment value 1,519.1 ± 141.7
- Corrective test: mistakes
- 6.4 ± 1.1 versus 9.7 ± 1.2Pre-treatment value 12.6 ± 1.3
Use. The US grant claims use of Glu-Asp-Arg for specified functional outcomes after brain-cortex injury.
This is a use claim with a disease-specific scope, not proof of general cognitive enhancement; family publications are not separate replications.
- Publication
- US8524674B2 ↗ · 2013-09-03
- Earliest priority / filing
- 2006-05-30 / 2012-08-15
- Original applicant / assignee
- SIA Peptides OOO
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 38171593 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of improving the conditioned reflex habit, the muscle tonus, or the motion coordination of a patient after suffering trauma to the brain cortex
Inventors: Vladimir Khatskelevich Khavinson; Evgeny Iosifovich Grigoriev; Vladimir Victorovich Malinin; Galina Anatolievna Ryzhak.
US8524674B2 · US20090105157A1 · EP2024388B1 · KR101289220B1 · ATE445633T1 · DE602006009848D1 · DK2024388T3 · EA010157B1 · IL194346A · RU2301678C1 · UA91136C2 · WO2007139431A1
Related profiles: Pinealon
Thymodepressin: monosodium crystal polymorph
Reported findings
The patent reports recovery of defined crystalline forms and conversion of a mixed preparation toward form F.
- Selected conversion result
- 38 mg recovered from a 50 mg portion, reported 78% yield; XRPD described as essentially form FAnalytical/manufacturing observation
- Different polymorph example
- Form X recovery reported at 60% yield, melting interval 182.3–186.1°CA different crystal form, not a clinical comparator
Formulation. This separate family concerns a particular monosodium crystalline form of the D-amino-acid dipeptide.
A distinct polymorph claim does not establish a different clinical mechanism or make every sodium formulation equivalent.
- Publication
- US8481588B2 ↗ · 2013-07-09
- Earliest priority / filing
- 2007-02-16 / 2012-06-07
- Original applicant / assignee
- Apotex Technologies Inc
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 39687890 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan
Inventors: Tim Fat Tam; Blaise N'Zemba; Regis Leung-Toung; Yingsheng Wang; Yanqing Zhao; Lily Yu.
US8481588B2 · US8207217B2 · US8592607B2 · US8664262B2 · EP2121727A4 · CN103319393B · CA2579119C · RU2476440C2 · WO2008098355A1
Related profiles: Thymodepressin
GHK and GQPR: combination compositions
Reported findings
The mixture cream improved selected ultrasound and confocal imaging measures of superficial dermal structure.
- Inner-forearm SLEB depth and density
- Placebo-adjusted changes: depth −11%, density approximately +15%2 monthsA thinner low-echogenic band and greater imaging density, not a clinical age reversal
- Outer-forearm imaging
- Depth/thickness −14.4%; density +15.1%2 monthsChanges reported for the light-exposed site
Formulation. This family describes peptide combinations involving GHK and GQPR, including lipid-modified variants.
A combination disclosure cannot identify the independent effect of GHK or be transferred to plain GHK-Cu.
- Publication
- WO2012164488A2 ↗ · 2012-12-06
- Earliest priority / filing
- 2011-06-01 / 2012-05-29
- Original applicant / assignee
- Sederma SA
- Indexed status
- Ceased · checked 2026-11-06
- Patent family
- 46246124 · family publications are related filings, not independent studies.
Original title, inventors and related publications
New cosmetic or dermopharmaceutical topical use of a mixture of a ghk tripeptide and gqpr tetrapeptide
Inventors: Arnaud Fournial; Philippe Mondon.
Related profiles: GHK-Cu & GHK family
Thymodepressin: crystalline salt development
Reported findings
The potassium example reports high analytical purity and low measured water content.
- Potassium-salt quality
- 98.3% HPLC peak-area purity; water content 0.7%Crystalline material characterized by diffraction; not a clinical efficacy endpoint
- Preparation recovery
- Reported quantitative yield in the potassium exampleManufacturing recovery, not response or bioavailability
Formulation. The disclosure discusses several salts, but the granted US claims narrow to a specified potassium crystal form.
The broader abstract is not the granted claim set; a crystal-form patent does not establish superiority in clinical treatment.
- Publication
- US8138221B2 ↗ · 2012-03-20
- Earliest priority / filing
- 2006-12-19 / 2007-12-13
- Original applicant / assignee
- Apotex Technologies Inc
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 39535926 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture
Inventors: Tim Fat Tam; Blaise N'Zemba; Regis Leung-Toung; Yingsheng Wang; Yanqing Zhao; Lily Yu.
US8138221B2 · US8735602B2 · EP2121729A4 · KR20090108034A · CN101611050B · AU2007335212B2 · CA2571645A1 · CL2007003680A1 · MX2009006673A · PE20121642A1 · RU2536685C2 · TWI406872B · UA106580C2 · UY30798A1 · WO2008074128A1
Related profiles: Thymodepressin
Crystagen research trail: defined EDP peptide
Reported findings
Selected T-cell markers changed during EDP-containing care, without established clinical immune-rejuvenation outcomes.
- CD3-positive cells
- 55.7 ± 2.6% after peptide-containing care versus 49.3 ± 2.2% conventional care; baseline 43.5 ± 2.3%Immune-marker endpoint; significance annotation has an ambiguous comparator footnote
- CD4/CD8 ratio
- 1.4 after peptide versus 1.2 conventional care; baseline 1.1Surrogate marker, not a disease or survival endpoint
Molecule. This family concerns the Glu-Asp-Pro sequence and proposed immune or geroprotective applications.
The sequence-level connection does not authenticate the composition or efficacy of a commercial Crystagen product.
- Publication
- US8057810B2 ↗ · 2011-11-15
- Earliest priority / filing
- 2006-05-30 / 2007-03-02
- Original applicant / assignee
- SIA Peptides OOO
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 38314259 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application
Inventors: Vladimir Khatskelevich Khavinson; Evgeny Iosifovich Grigoriev; Vladimir Victorivich Malinin; Galina Anatolievna Ryzhak.
US8057810B2 · EP2032595B1 · KR101382947B1 · ATE513845T1 · DK2032595T3 · EA010575B1 · IL194499A0 · RU2301074C1 · UA91135C2 · WO2007139435A1
Related profiles: Crystagen
Dilept: defined peptide-derived formulation
Narrative findings; numerical extraction incomplete
The patent reports producing solid dosage forms that meet stated quality requirements.
- Formulation outcome
- Example tablets/capsules are reported to meet pharmacopoeial requirementsA manufacturing claim supported by preparation examples, not a clinical response
- Quality specifications
- Capsule disintegration limit ≤20 minutes; impurity limits ≤0.5% individually and ≤1% totalThese are acceptance limits, not measured patient outcomes or observed batch values
Formulation. The patent identifies a formulation involving N-caproyl-L-prolyl-L-tyrosine methyl ester.
Exact chemical identity matters; the formulation patent does not establish comparative antipsychotic efficacy.
- Publication
- RU2420304C2 ↗ · 2011-06-10
- Earliest priority / filing
- 2009-01-15 / 2009-01-15
- Original applicant / assignee
- Учреждение Российской Академии Медицинских Наук Научно-Исследовательский Институт Фармакологии Имени В.В.Закусова Рамн
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 42685698 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition with antipsychotic action
Inventors: Сергей Борисович Середенин (RU); Сергей Борисович Середенин; Борис Михайлович Пятин (RU); Борис Михайлович Пятин; Нина Ивановна Авдюнина (RU); Нина Ивановна Авдюнина; Константин Викторович Алексеев (RU); Константин Викторович Алексеев; Любовь Николаевна Грушевская (RU); Любовь Николаевна Грушевская; Евгения Викторовна Блынская (RU); Евгения Викторовна Блынская; Раиса Филипповна Большакова (RU); Раиса Филипповна Большакова; Максим Владимирович Гусев (RU); Максим Владимирович Гусев; Ольга Михайловна Шендера (RU); Ольга Михайловна Шендера.
Related profiles: Dilept
KED / Vesugen: defined peptide and microcirculation claims
Reported findings
The patent reports improved cuff-test resistance and changes in coagulation measures after ten days.
- Cuff test
- Treated group III–IV → II; control III–IV → III–IV10-day courseOrdinal capillary-resistance measure
- Recalcification time
- 164.2 ± 2.4 with KED versus 147.3 ± 4.2 controlHealthy comparison value 178.0 ± 14.0; not a clinical vascular event
Molecule. The granted claims explicitly identify H-Lys-Glu-Asp-OH and compositions or methods involving microcirculation disorders.
Defined KED is not automatically identical to a branded multicomponent capsule or vascular tissue extract.
- Publication
- US7851449B2 ↗ · 2010-12-14
- Earliest priority / filing
- 2006-05-23 / 2006-12-04
- Original applicant / assignee
- SIA Peptides OOO
- Indexed status
- Active - Reinstated · checked 2026-11-06
- Patent family
- 37999085 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide, pharmaceutical composition, and a method of treating microcirculation disorders
Inventors: Vladimir Khatskelevich Khavinson; Evgeny Iosifovich Grigoriev; Vladimir Victorovich Malinin; Galina Anatolievna Ryzhak.
US7851449B2 · EP2024387B1 · KR20090009867A · ATE446309T1 · DE602006009976D1 · DK2024387T3 · EA010158B1 · IL194500A · RU2295970C1 · UA91137C2 · WO2007136294A1
Imunofan: adjunctive steroid-resistance claim
Reported findings
A reported rheumatoid-arthritis/uveitis case improved during combined treatment, with immunological changes and an eight-month remission.
- Illustrative case: inflammatory markers
- ESR 40 → 5; ocular autoantibody titer 1:512 → 1:128After the courseBefore/after combined treatment; not a controlled comparison
- Illustrative case: visual acuity
- Right eye improved to 0.9; left eye to 0.02After the coursePost-treatment values; do not interpret as change scores without the baseline
Use. The patent proposes Imunofan in a method addressing resistance to glucocorticoid treatment.
An adjunctive method claim does not establish generalized immune tolerance or autoimmune disease-modifying efficacy.
- Publication
- RU2404792C1 ↗ · 2010-11-27
- Earliest priority / filing
- 2009-05-20 / 2009-05-20
- Original applicant / assignee
- Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 44057532 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent for coping with steroid resistance
Inventors: Василий Вячеславович Лебедев (RU); Василий Вячеславович Лебедев; Татьяна Владимировна Величко (RU); Татьяна Владимировна Величко.
Related profiles: Imunofan
APHC family: additional analgesic peptide variants
Reported findings
The variants differed in temperature effects, illustrating that related peptides are not interchangeable.
- Temperature decrease
- Approximately 0.5–1°C reported for APHC1 around 40 minutes and APHC3 around 80 minutesAn animal physiological effect, not a clinical therapeutic endpoint
- Neutral variant
- No significant body-temperature decrease detected with APHC2Variant-specific neutral observation retained
Molecule. The claim defines related sea-anemone peptide variants with specified amino-acid substitutions.
Family-level sequence claims must not be transferred to unrelated marine peptides; human clinical efficacy has not been established here.
- Publication
- RU2404245C1 ↗ · 2010-11-20
- Earliest priority / filing
- 2009-07-09 / 2009-07-09
- Original applicant / assignee
- Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 44058440 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Actinia polypeptide, possessing analgesic action
Inventors: Сергей Александрович Козлов (RU); Сергей Александрович Козлов; Ярослав Алексеевич Андреев (RU); Ярослав Алексеевич Андреев; Аркадий Николаевич Мурашев (RU); Аркадий Николаевич Мурашев; Евгений Васильевич Гришин (RU); Евгений Васильевич Гришин.
Related profiles: APHC peptide family
Peptide substance restoring myocardium function — US7662789B2
Reported findings
The patent reports altered cellular respiration under oxygen deprivation and leukocyte changes in longer animal observations.
- Succinate-related respiration coefficient
- 7.35 ± 0.26 in oxygen-deprived cells versus 1.97 ± 0.26 after peptideCellular respiration ratio; oxygen consumption in normally oxygenated cells was not altered
- Animal leukocytes
- 11.2 ± 0.8 versus 9.4 ± 0.5 control at 3 months; 11.9 ± 0.5 versus 9.6 ± 0.5 at 6 months×10^9/L; 24 animals per displayed group
Molecule. The claim concerns Ala-Glu-Asp-Arg (AEDR), the Cardiogen sequence; EP1758923 belongs to this family and is not the respiratory AEDL peptide.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- US7662789B2 ↗ · 2010-02-16
- Earliest priority / filing
- 2004-06-22 / 2004-12-07
- Original applicant / assignee
- Access Bioscience CJSC
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 34960195 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide substance restoring myocardium function
Inventors: Vladimir Khatskelevich Khavinson; Galina Anatolievna Ryzhak; Evgeny Iosifovich Grigoriev; Irina Yurievna Ryadnova.
US7662789B2 · EP1758923B8 · ATE386047T1 · DE602004011843T2 · ES2302067T3 · RU2255756C1 · WO2006001728A1
Related profiles: Cardiogen
Ladasten: pharmaceutical composition
Reported findings
The disclosure reports acceptable tablet disintegration and mechanical properties.
- Example tablet disintegration
- 6–7 minutesA reported manufacturing-example result, not onset of clinical action
- Direct-compression tablet properties
- Compressive strength 47.81 ± 1.5 N; abrasion resistance 99.7 ± 0.6%Physical formulation measurements; table also specifies disintegration ≤15 minutes
Formulation. The claims concern a formulated Ladasten preparation, including the active ingredient and excipients.
A formulation claim is narrower than ownership of every use of bromantane and does not establish comparative clinical benefit.
- Publication
- RU2376986C2 ↗ · 2009-12-27
- Earliest priority / filing
- 2006-11-30 / 2006-11-30
- Original applicant / assignee
- Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 41643188 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition based on ladasten
Inventors: Сергей Борисович Середенин (RU); Сергей Борисович Середенин; Борис Михайлович Пятин (RU); Борис Михайлович Пятин; Нина Ивановна Авдюнина (RU); Нина Ивановна Авдюнина; Константин Викторович Алексеев (RU); Константин Викторович Алексеев; Любовь Николаевна Грушевская (RU); Любовь Николаевна Грушевская; Александр Сергеевич Сульдин (RU); Александр Сергеевич Сульдин.
Related profiles: Bromantane
Bronchogen: AEDL respiratory peptide
Narrative findings; numerical extraction incomplete
The patent reports lower lung-injury changes and stimulation of explant growth, with selected blood-count changes during longer exposure.
- Lung-injury findings
- Less interstitial fibrosis, atelectatic change and cellular infiltration describedExperimental animal comparison; no transcribed clinical lung-function effect
- Organotypic lung growth
- Explant growth significantly stimulated over the stated 1–10 ng/mL rangeLaboratory tissue model; not human airway regeneration
Molecule. Claim 1 explicitly identifies the tetrapeptide Ala-Glu-Asp-Leu, with respiratory-function composition and method claims.
This is AEDL, not the EDG tripeptide Chonluten. A respiratory label or a secondary review citation cannot resolve that sequence difference.
- Publication
- US7625870B2 ↗ · 2009-12-01
- Earliest priority / filing
- 2004-06-22 / 2004-12-07
- Original applicant / assignee
- Access Bioscience CJSC
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 34960198 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide substance restoring respiratory organs function
Inventors: Vladimir Khatskelevich Khavinson; Galina Anatolievna Ryzhak; Evgeny Iosifovich Grigoriev; Irina Yurievna Ryadnova.
US7625870B2 · EP1758922B8 · ATE386046T1 · DE602004011842T2 · ES2302068T3 · RU2255757C1 · WO2006001729A1
Related profiles: Bronchogen
Retinalamin plus Cortexin: optic-nerve and retinal method
Reported findings
Visual improvement was reported in some eyes, with a persistent non-response in a blind eye.
- Glaucoma case: right eye
- Corrected visual acuity 0.3 → 0.5; total visual-field expansion reported as 40°After a 10-day courseCombined care in one 76-year-old patient
- Glaucoma case: left eye
- Visual acuity remained 0After the courseThe eye had longstanding blindness; no recovery was reported
Use. The method combines Retinalamin and Cortexin with physical-treatment procedures for optic-nerve or retinal disease.
Combined treatment and patent case examples do not establish either extract's independent benefit or validate a new administration route.
- Publication
- RU2373904C1 ↗ · 2009-11-27
- Earliest priority / filing
- 2008-07-08 / 2008-07-08
- Original applicant / assignee
- Ольга Геннадьевна Гусаревич
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 41476515 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of treating diseases of optic nerve and retina
Inventors: Ольга Геннадьевна Гусаревич (RU); Ольга Геннадьевна Гусаревич; Анна Аркадьевна Гусаревич (RU); Анна Аркадьевна Гусаревич; Анжелла Жановна Фурсова (RU); Анжелла Жановна Фурсова.
Related profiles: Retinalamin · Cortexin
APHC1: sea-anemone peptide claim
Reported findings
APHC1 produced partial, reversible channel inhibition and a delayed analgesic-like response in the mouse test.
- Channel response
- Maximum inhibition reported as 32 ± 9% on average, with a highest value of 50%Partial, reversible inhibition; not complete channel blockade
- Mouse analgesic time course
- Effect developed over approximately 1–2 hours and lasted more than 2 hoursSmall experimental assay; not human pain relief duration
Molecule. The claim explicitly names APHC1 and defines the analgesic peptide.
A molecular claim is not proof of human analgesia. APHC peptides differ from HCRG21 and the Hcr ASIC research family.
- Publication
- RU2368621C1 ↗ · 2009-09-27
- Earliest priority / filing
- 2008-04-04 / 2008-04-04
- Original applicant / assignee
- Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 41169539 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Actinia polypeptide having analgetic action
Inventors: Сергей Александрович Козлов (RU); Сергей Александрович Козлов; Ярослав Алексеевич Андреев (RU); Ярослав Алексеевич Андреев; Сергей Геннадьевич Кошелев (RU); Сергей Геннадьевич Кошелев; Екатерина Александровна Иванова (RU); Екатерина Александровна Иванова; Елена Владимировна Лейченко (RU); Елена Владимировна Лейченко; Эмма Павловна Козловская (RU); Эмма Павловна Козловская; Евгений Васильевич Гришин (RU); Евгений Васильевич Гришин.
Related profiles: APHC peptide family
PCC: corrected cartilage-complex publication
Narrative findings; numerical extraction incomplete
Pain reduction is reported, but the percentage and patient count do not yield a clear responder denominator.
- Pain improvement
- Reported in 67.4% of casesAfter a 20-day courseThe text does not explain how this percentage maps to the 15 treated participants
- Cartilage-culture findings
- Growth-stimulation experiments described in rat cartilage fragmentsLaboratory tissue findings are separate from the patient pain report
Manufacturing. The corrected C9 publication claims a cartilage-derived peptide complex and its production. The related C1 record contains mismatched ovarian claim text.
Use the corrected claim text, not the erroneous C1 text, when tracing the cartilage preparation. A tissue complex is not a single defined peptide.
- Publication
- RU2302872C9 ↗ · 2008-12-20
- Earliest priority / filing
- 2006-06-22 / 2006-06-22
- Original applicant / assignee
- Общество С Ограниченной Ответственностью "Сиа Пептайдс"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 38431016 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent normalizing cartilage tissue function and method for its preparing
Inventors: Владимир Хацкелевич Хавинсон (RU); Владимир Хацкелевич Хавинсон; Владимир Викторович Малинин (RU); Владимир Викторович Малинин; Галина Анатольевна Рыжак (RU); Галина Анатольевна Рыжак.
Related profiles: PCC
Noopept: injectable stroke formulation
Reported findings
Several histological and behavioral measures favored Noopept, while not every cortical section differed.
- Cortical injury score: section 1
- 0.06 ± 0.01 treated versus 0.50 ± 0.11 salineHistology subset; ordinal injury score
- Cortical injury score: section 3
- 0.80 ± 0.20 versus 1.38 ± 0.22Sections 4–5 were not marked significant
Formulation. The claims concern an injectable Noopept formulation proposed for acute ischemic stroke.
A formulation patent does not establish regulatory approval, clinical stroke benefit or interchangeability with oral preparations.
- Publication
- RU2330680C2 ↗ · 2008-08-10
- Earliest priority / filing
- 2005-12-09 / 2005-12-09
- Original applicant / assignee
- Государственное учреждение Научно-исследовательский институт фармакологии имени В.В. Закусова Российской академии медицинских наук
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 38314867 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Injection dosage form for acute stroke treatment, method of production and application thereof
Inventors: Сергей Борисович Середенин (RU); Сергей Борисович Середенин; Рита Ушеровна Островска (RU); Рита Ушеровна Островская; тин Борис Михайлович П (RU); Борис Михайлович Пятин; Тать на Александровна Воронина (RU); Татьяна Александровна Воронина; Тать на Александровна Гудашева (RU); Татьяна Александровна Гудашева; Константин Викторович Алексеев (RU); Константин Викторович Алексеев; Любовь Николаевна Грушевска (RU); Любовь Николаевна Грушевская.
Related profiles: Noopept
Dalargin and electropuncture for acute hearing injury after mine blasts — RU2323019C1
Reported findings
Hearing improved in some patients, while 43% had no reported treatment effect.
- Hearing outcome
- 22.3% complete restoration, 34.7% improvement, 43% unchangedAfter the treatment courseReported proportions; no modern randomized comparison established
- Hearing thresholds
- Average reductions reported in the 15–30 dB rangeWithin-cohort change across speech/high frequencies
Use. A Dalargin method relating to blast-associated hearing injury; disease-specific patent claims do not establish routine clinical benefit.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2323019C1 ↗ · 2008-04-27
- Earliest priority / filing
- 2006-11-23 / 2006-11-23
- Original applicant / assignee
- Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 39453032 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for treating patients for posttraumatic sensorineural deafness in acute stage caused by mine explosion injury
Inventors: Эльвира Татаркановна Гаппоева (RU); Эльвира Татаркановна Гаппоева.
Related profiles: Dalargin
Vinpotropil: vinpocetine plus piracetam
Reported findings
The patent reports improvement in anxiety and selected attention/symptom measures, with neutral depression comparisons.
- Anxiety score
- Vinpotropil 32.7 → 17.6; other displayed groups 30.1 → 26.5, 30.0 → 22.3 and 31.5 → 24.721 daysSpielberger score; before/after significance is not a verified between-group treatment effect
- Depression score
- Vinpotropil 21.1 → 20.2; no significant differences reported in any group21 daysNeutral depression result retained
Formulation. The patent describes the combination composition containing vinpocetine and piracetam.
A fixed-combination claim does not establish either ingredient's independent effect or demonstrate pharmacological synergy.
- Publication
- EA009666B1 ↗ · 2008-02-28
- Earliest priority / filing
- 2003-11-03 / 2004-10-29
- Original applicant / assignee
- Закрытое Акционерное Общество "Канонфарма Продакшн"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 34545985 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition exhibiting a cerebral vasodilatation and nootropic activity
Inventors: Not established from accessed metadata.
Related profiles: Vinpotropil · Piracetam
AED bone/cartilage composition and reported knee-osteoarthritis comparison — RU2299741C1
Reported findings
The patent reports less pain and better knee mobility after 20 days of intramuscular AED. It reports no substantial X-ray change.
- Pain and joint mobility
- Improvement reported in 54.5–62.7% of cases20-day courseRange across disease-severity subgroups; subgroup counts and control response are not reported
- X-ray findings
- No substantial radiographic changeDuring the reported treatment period
Molecule. The claim explicitly identifies Ala-Glu-Asp (AED), with bone/cartilage applications; this is not the cartilage-derived PCC mixture.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2299741C1 ↗ · 2007-05-27
- Earliest priority / filing
- 2006-05-30 / 2006-05-30
- Original applicant / assignee
- Общество С Ограниченной Ответственностью "Сиа Пептайдс"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 38310627 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide normalizing metabolism in osseous and cartilage tissue, pharmaceutical composition based on thereof and method for its using
Inventors: Владимир Хацкелевич Хавинсон (RU); Владимир Хацкелевич Хавинсон; Евгений Иосифович Григорьев (RU); Евгений Иосифович Григорьев; Владимир Викторович Малинин (RU); Владимир Викторович Малинин; Галина Анатольевна Рыжак (RU); Галина Анатольевна Рыжак.
Related profiles: Cartalax
EDL: defined liver-regeneration peptide
Reported findings
The patent reports greater bilirubin reduction with EDL-containing care and a before/after ALT change.
- Bilirubin
- 18.6 ± 1.4 after EDL versus 22.3 ± 1.1 conventional care; baseline 27.4 ± 1.7Table’s blanket unit label is unsuitable for all analytes; no corrected unit invented
- ALT
- 41.7 ± 2.9 after EDL versus 46.2 ± 3.8 conventional care; baseline 54.5 ± 4.9Marked significant versus baseline, not clearly versus conventional care
Molecule. The claims identify H-Glu-Asp-Leu-OH and related liver-regeneration compositions or uses.
The EDL sequence must not be confused with AEDL Bronchogen; commercial Ovagen equivalence has not been established here.
- Publication
- RU2297239C1 ↗ · 2007-04-20
- Earliest priority / filing
- 2006-05-30 / 2006-05-30
- Original applicant / assignee
- Общество С Ограниченной Ответственностью "Сиа Пептайдс"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 38036774 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide stimulating regeneration of liver tissue, pharmaceutical composition based on thereof and method for its using
Inventors: Владимир Хацкелевич Хавинсон (RU); Владимир Хацкелевич Хавинсон; Евгений Иосифович Григорьев (RU); Евгений Иосифович Григорьев; Владимир Викторович Малинин (RU); Владимир Викторович Малинин; Галина Анатольевна Рыжак (RU); Галина Анатольевна Рыжак.
Related profiles: EDL
Cortagen: AEDP molecular and neuronal-use claims
Reported findings
The trauma comparison reports better test scores during Cortagen-containing care. The dementia percentage claim is not consistent with a straightforward 12-person responder count.
- Trauma corrective test: characters
- 2,519.6 ± 105.3 Cortagen, 2,193.3 ± 120.6 Cerebrolysin, 1,977.4 ± 186.4 conventional careThree patent-described treatment groups
- Trauma corrective test: mistakes
- 6.3 ± 1.1, 9.4 ± 1.7 and 10.5 ± 1.9, respectivelySame group order; not a blinded modern cognitive trial
Molecule. The claims identify Ala-Glu-Asp-Pro and related neuronal-function compositions and uses.
The defined tetrapeptide differs from the Cortexin extract; proposed neuronal effects are not established clinical outcomes.
- Publication
- US7189701B1 ↗ · 2007-03-13
- Earliest priority / filing
- 1999-10-20 / 2000-05-25
- Original applicant / assignee
- Nostiji "Klinika Instituta Bioregulyatsii Gerontologii" OOO
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 20225904 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Tetrapeptide stimulating functional activity of neurons pharmacological agent based thereon and method of use thereof
Inventors: Vladimir K. Khavinson; Vyacheslav G. Morozov; Vladimir V. Malinin; Evgeny I. Grigoriev.
US7189701B1 · EP1224212B1 · JP4668497B2 · ATE244727T1 · AU784578B2 · CA2388357A1 · DE60003837T2 · IL149243A0 · RU2155063C1 · WO2001029067A1
Related profiles: Cortagen
Livagen: KEDA molecular and hepatocyte-use claims
Reported findings
The patent reports changes in selected liver and immune markers during treatment.
- Bilirubin
- 26.3 ± 1.8 → 21.7 ± 1.5Source table’s blanket units are questionable for different analytes, so no unit correction is invented
- ALT
- 53.1 ± 4.7 → 40.8 ± 3.1Before/after; no established controlled treatment effect
Molecule. The claims specify Lys-Glu-Asp-Ala and compositions or uses directed at hepatocyte function.
Molecular identity and a patent use claim do not establish treatment of human liver disease.
- Publication
- US7101854B2 ↗ · 2006-09-05
- Earliest priority / filing
- 2000-10-09 / 2001-05-15
- Original applicant / assignee
- Nostiji "Klinika Instituta Bioregulyatsii Gerontologii" OOO
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 20240745 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Tetrapeptide stimulating the functional activity of hepatocytes, pharmacological substance on its basis and the method of its application
Inventors: Vladimir Khatskelevich Khavinson.
US7101854B2 · EP1325026B1 · ATE273994T1 · AU2001266441A1 · CA2425445C · DE60105042T2 · RU2166957C1 · WO2002030955A2
Related profiles: Livagen
Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application
Reported findings
The clinical examples describe improvement during adjunctive Bemitil treatment, without group-level efficacy scores or a controlled patient comparison.
- MS illustrative case
- Reported clinical/MRI remission, improved strength, coordination, memory, mood and sleepAfter approximately 3 weeksOne 47-year-old patient also receiving piracetam, pentoxifylline and vitamins
- Chronic-fatigue illustrative case
- Reported improvement in general condition, tremor, headaches, coordination and perceived weaknessAfter a 15-day courseOne 29-year-old patient receiving several other medicines
Use. Bemitil in multiple sclerosis, with a small historical case series and concurrent treatment; not a controlled MS efficacy trial.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2267319C2 ↗ · 2006-01-10
- Earliest priority / filing
- 2003-07-15 / 2003-07-15
- Original applicant / assignee
- Общество с ограниченной ответственностью "Интер-Кэр"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 35208242 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application
Inventors: Олег Валентинович Дорожко (RU); Олег Валентинович Дорожко; Георгий Иванович Ковалев (RU); Георгий Иванович Ковалев; Рамиз Меджидович Салимов (RU); Рамиз Меджидович Салимов.
Related profiles: Bemitil
Semax: stroke-oriented pharmaceutical composition
Reported findings
The patent reports faster neurological regression, with incompletely specified subgroup percentage denominators.
- Moderate-stroke course
- Regression reported in 88% with Semax versus 55.2% controlPercentages retained as printed; subgroup denominators do not map cleanly to these values
- Moderate-stroke functional recovery
- 80% reported good recovery and 36% complete focal-symptom regressionEnd of acute periodPatent narrative; no prespecified modern functional endpoint established
Formulation. The patent concerns a Semax formulation proposed for stroke-related applications.
A formulation filing is not a newly completed stroke trial or proof of healthy-person cognitive enhancement.
- Publication
- RU2251429C2 ↗ · 2005-05-10
- Earliest priority / filing
- 2002-12-30 / 2002-12-30
- Original applicant / assignee
- Институт Молекулярной Генетики Российской Академии Наук (Имг Ран)
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 35747098 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition for treating ischemic insult and method for therapy
Inventors: И.П. Ашмарин (RU); И.П. Ашмарин; Л.Ю. Алфеева (RU); Л.Ю. Алфеева; Л.А. Андреева (RU); Л.А. Андреева; И.А. Гривенников (RU); И.А. Гривенников; Е.И. Гусев (RU); Е.И. Гусев; О.В. Долотов (RU); О.В. Долотов; А.А. Каменский (RU); А.А. Каменский; соедов Н.Ф. М (RU); Н.Ф. Мясоедов; В.Н. Незавибатько (RU); В.Н. Незавибатько; А.В. Немерский (RU); А.В. Немерский; В.И. Скворцова (RU); В.И. Скворцова.
Related profiles: Semax
Method of pharmacological correction of human work capacity in extreme situations
No measured outcomes in the accessed disclosure
The accessed disclosure specifies a scheme but does not supply an extractable treatment cohort or measured comparative outcomes.
- Clinical or performance results
- No participant denominator, endpoint values or controlled effect estimate reported in the accessed descriptionThe claimed effectiveness is not a measured result
Use. Hypoxen-related use under extreme conditions; patent examples are separate from controlled clinical confirmation.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- EA005383B1 ↗ · 2005-02-24
- Earliest priority / filing
- 2001-12-28 / 2001-12-28
- Original applicant / assignee
- Федеральное Государственное Унитарное Предприятие "Центр Экстремальной Медицины"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 34585798 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for pharmacological correction of human's efficiency under extreme conditions
Inventors: Евгений Георгиевич Жиляев; Павел Михайлович Шалимов; Дмитрий Валерьевич Глухов; Андрей Геннадьевич Жиляев; Сергей Егорович Макаров; Григорий Георгиевич Незнамов.
Related profiles: Hypoxen / Olifen
Pancragen trail: terminally amidated KEDW
Reported findings
Selected cases report lower glucose and reduced background medication requirements; no independent peptide effect is established.
- Insulin-treated case
- Fasting glucose 17.8 → 3.4 mmol/L; insulin 40 → 32 units/dayDischarge on day 15One individual; concurrent care continued
- Oral-treatment case
- Fasting glucose 11 → 6 mmol/L by day 2; background oral drug subsequently reducedDay 2 and subsequent courseOne selected patient, not a randomized comparison
Molecule. The patent describes Lys-Glu-Asp-Trp with a terminal amide, alongside pancreatic-function applications.
Terminal chemistry matters: the claimed KEDW-NH2 must not be assumed identical to every KEDW product with a free acid terminus.
- Publication
- RU2242241C1 ↗ · 2004-12-20
- Earliest priority / filing
- 2003-12-10 / 2003-12-10
- Original applicant / assignee
- Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 34388701 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Tetrapeptide regulating glucose level in diabetes mellitus, pharmacological agent based on thereof and method for its applying
Inventors: В.Х. Хавинсон (RU); В.Х. Хавинсон; В.В. Малинин (RU); В.В. Малинин; Е.И. Григорьев (RU); Е.И. Григорьев; Г.А. Рыжак (RU); Г.А. Рыжак.
RU2242241C1 · US7491703B2 · EP1697401B1 · JP2007537140A · KR101106609B1 · ATE454397T1 · AU2004296269B2 · CA2547873C · DE602004025040D1 · DK1697401T3 · EA008541B1 · LT5421B · LV13462B · UA85204C2 · WO2005056580A1
Related profiles: Pancragen
Phenotropil: antidepressant-use patent
Narrative findings; numerical extraction incomplete
The clinical section reports antidepressant activity but does not provide independently transcribed Hamilton score changes.
- Clinical depression scale
- Hamilton-scale improvement reported for PhenotropilExact baseline/endpoint means, uncertainty and responder counts are not entered
- Comparator claim
- The narrative states activity was not inferior to amitriptylineNo prespecified noninferiority margin or adequate noninferiority analysis established
Use. The Russian document proposes phenylpiracetam for an antidepressant application.
Patent experimental claims are not a completed modern clinical depression trial.
- Publication
- RU2232578C1 ↗ · 2004-07-20
- Earliest priority / filing
- 2003-04-10 / 2003-04-10
- Original applicant / assignee
- Ахапкина Валентина Ивановна
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 33157471 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Substance eliciting antidepressant activity
Inventors: В.И. Ахапкина (RU); В.И. Ахапкина; Р.В. Ахапкин (RU); Р.В. Ахапкин; Ю.А. Александровский (RU); Ю.А. Александровский; А.С. Аведисова (RU); А.С. Аведисова; Т.А. Воронина (RU); Т.А. Воронина; В.В. Нестерук (RU); В.В. Нестерук.
RU2232578C1 · US20060287383A1 · EP1619182B1 · CA2521923C · CY1115549T1 · DK1619182T3 · EA009044B1 · ES2486844T3 · PL1619182T3 · PT1619182E · SI1619182T1 · WO2004089893A1
Related profiles: Phenotropil
Epitalon: AEDG molecular patent
Reported findings
Epitalon results vary by species, sex, strain and endpoint; the patent does not demonstrate longer human life.
- HEM female flies: average lifespan
- 48 ± 1.5 days treated versus 38 ± 1.6 controlA fly experiment, not human survival
- LA female flies: average versus maximum lifespan
- Average 20 ± 1.3 versus 22 ± 1.0 days; maximum 44 ± 1.9 versus 36 ± 1.9 days Maximum lifespan improved while average lifespan did not; separate endpoints
Molecule. The patent claims the defined tetrapeptide Ala-Glu-Asp-Gly, related compositions and proposed uses.
The synthetic peptide differs from Epithalamin extract. Patent geroprotection claims do not demonstrate extension of human lifespan.
- Publication
- US6727227B1 ↗ · 2004-04-27
- Earliest priority / filing
- 1999-05-11 / 2000-01-20
- Original applicant / assignee
- Nostiji "Klinika Instituta Bioregulyatsii Gerontologii" OOO
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 20219149 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Tetrapetide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application
Inventors: Vladimir K. Khavinson.
US6727227B1 · EP1179008B1 · JP3902406B2 · ATE321068T1 · AU769847C · CA2373128C · DE60026826T2 · ES2259998T3 · IL146432A0 · RU2157233C1 · WO2000068255A2
Related profiles: Epitalon
Hypoxen: complement-pathway inhibition lead
Narrative findings; numerical extraction incomplete
The experiments support a complement-interaction hypothesis rather than established clinical immune control.
- C1q-related activity
- Concentration-dependent inhibition of C1q-associated activity reportedLaboratory complement system, not autoimmune disease activity
- Affinity-value ambiguity
- The indexed text has an unclear exponent in the stated affinity value; no corrected binding constant is enteredAn OCR/exponent problem can change the value by many orders of magnitude
Use. This use patent proposes Hypoxen in relation to C1q/C1 complement inhibition.
A mechanistic patent lead is not evidence of clinical autoimmune disease control or selective immune tolerance.
- Publication
- RU2205002C1 ↗ · 2003-05-27
- Earliest priority / filing
- 2002-07-11 / 2002-07-11
- Original applicant / assignee
- Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н.Габричевского"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20255843 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Hypoxen as inhibitor of c1q subcomponent and c1 component of human complement system
Inventors: Б.Б. Шойбонов; А.Н. Онтобоев; А.А. Зинченко; В.А. Алёшкин.
Related profiles: Hypoxen / Olifen
Original Cyclontane / ADK-638 patent trail
Narrative findings; numerical extraction incomplete
The patent reports increased running-to-exhaustion performance and stimulant-related behavioral effects.
- Treadmill performance
- Significantly longer running-to-exhaustion at selected tested exposures8 rats per group; exact table means not transcribed
- Behavioral pharmacology
- Anti-cataleptic activity and stimulant-like responses describedModel-specific comparisons do not establish human superiority to Bromantane
Molecule. Cyclontane development patent; the compound identity is distinct from related cage amides and comparator agents.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2196575C2 ↗ · 2003-01-20
- Earliest priority / filing
- 1999-07-30 / 1999-07-30
- Original applicant / assignee
- Научно-исследовательский институт фармакологии РАМН
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20223238 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Substance eliciting psychostimulating and antiasthenic effect
Inventors: С.Б. Середенин; И.С. Морозов; Г.Г. Незнамов; Н.В. Климова; Н.И. Авдюнина; И.А. Иванова; С.А. Сергеева; Г.И. Ковалев; Б.М. Пятин; Е.А. Вальдман; О.А. Михайлова; Н.А. Кисляк; О.В. Щербакова; О.Б. Степаненко; Е.А. Цветкова.
Related profiles: Cyclontane
Retinalamin / Cortexin: local ocular delivery method
Reported findings
The patent reports visual gains and persistence over follow-up, with two advanced-disease eyes showing no objective benefit.
- Visual acuity and fields
- Acuity increases of 0.01–0.4 and field expansion averaging 10–15° reported1 weekBefore/after; not an untreated comparison
- Additional acuity and field changes
- Acuity increased a further 0.05–0.2; fields expanded a further 5–10°1 monthRelative to the preceding examination, as described
Use. The patent describes a surgical delivery method involving retina- or brain-cortex-derived peptide preparations; the description identifies Retinalamin and Cortexin.
This is a delivery-method disclosure, not proof of safety or superiority of an invasive route. It must not be counted as independent clinical replication without checking related reports.
- Publication
- RU2195297C2 ↗ · 2002-12-27
- Earliest priority / filing
- 2000-01-20 / 2000-01-20
- Original applicant / assignee
- Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20229433 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for treating dystrophic diseases of eyes
Inventors: И.Б. Максимов; В.Х. Хавинсон; Л.К. Мошетова; Г.В. Анисимова.
Related profiles: Retinalamin · Cortexin
Myelopeptides and their therapeutic use — US6469137B1
Reported findings
MP-4 induced a differentiation-like phenotype in leukemia cells; the individual myelopeptides did not act uniformly across the assays.
- MP-4 leukemia-cell differentiation
- Approximately 60% mature monocyte/macrophage forms reported among the examined cellsIn-vitro morphology endpoint, not a leukemia remission rate
- Short-term viability
- No visible damage reported for the tested MP-3–MP-6 cell-culture conditions24-hour observationA limited cell assay, not clinical or long-term safety
Molecule. Defined myelopeptide-related sequences and their proposed immune applications; the patent does not validate every Myelopid preparation.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- US6469137B1 ↗ · 2002-10-22
- Earliest priority / filing
- 1997-01-07 / 1998-01-07
- Original applicant / assignee
- Primamedic Ltd
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 10805577 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Myelopeptides and their therapeutic use
Inventors: Rem V. Petrov; Augusta A. Mikhailova; Larissa A. Fonina; Sergei A. Guriyanov.
US6469137B1 · US20030083236A1 · EP0960122A1 · JP2001508435A · AU728539B2 · CA2274731A1 · GB9700154D0 · NZ336243A · RU2198178C2 · WO1998030581A1
Related profiles: Myelopid & MP-1–MP-6
Prostamax: KEDP molecular and prostate-use claims
Narrative findings; numerical extraction incomplete
The patent reports urinary-symptom improvement, but the displayed clinical percentages have incompletely specified denominators.
- Prostatitis symptoms
- Reported cessation of frequent urination in 87.5% and difficult urination in 80.7%Narrative percentages; no verified responder counts inferred
- Adenoma comparison
- Subjective and urodynamic improvement reported; increased libido stated in 37.3%19 treated patients; 37.3% does not map cleanly to an integer count in this group
Molecule. The patent identifies Lys-Glu-Asp-Pro and proposed prostate-function applications.
This peptide is not a generic prostate extract or an unrelated supplement sold under a similar name.
- Publication
- RU2177802C1 ↗ · 2002-01-10
- Earliest priority / filing
- 2001-01-25 / 2001-01-25
- Original applicant / assignee
- Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20245158 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Tetrapeptide regulating prostate function, pharmacological agent based on thereof and method of its using
Inventors: В.Х. Хавинсон; В.В. Малинин; Е.И. Григорьев.
RU2177802C1 · EP1353939B1 · ATE274523T1 · AU2002221216A1 · DE60105204T2 · WO2002066497A2
Related profiles: Prostamax
Normophthal / Lys-Glu: ocular angiogenesis use
Reported findings
The patent describes faster improvement in corneal inflammation and reduced neovascular activity with adjunctive Lys-Glu.
- Corneal comparison
- Faster reduction of photophobia, tearing and inflammation than conventional care reported39 treated versus 16 comparison patients; numerical between-group estimate not extracted
- Posterior-eye report
- Scotoma number/size reportedly decreased in 87.3% of cases; perifocal edema disappeared in 52.4% and decreased in 43.2%The percentages’ patient-versus-eye denominators are not sufficiently explicit
Use. The claim explicitly identifies L-Lys-L-Glu in an ophthalmic angiogenesis-inhibition use. This is the same defined sequence discussed for Vilon, with a different proposed application.
A shared sequence does not make every branded formulation equivalent, and an ocular method claim does not establish human visual benefit.
- Publication
- RU2177801C1 ↗ · 2002-01-10
- Earliest priority / filing
- 2001-01-25 / 2001-01-25
- Original applicant / assignee
- Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20245157 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent inhibiting angiogenesis in visual organ disease
Inventors: В.Х. Хавинсон; В.М. Хокканен; С.В. Трофимова; В.В. Малинин.
Related profiles: Normophthal · Vilon
Anxiolytic use of the known Bromantane molecule — RU2175229C2
Narrative findings; numerical extraction incomplete
The patent reports less fear-related behavior with greater exploration, alongside behavioral activation.
- Maze/exploration result
- Reduced fear-like response in the high-fear strain and increased activity in the more exploratory strainNo transcribed group means or human anxiety outcome
- Diazepam comparison
- The disclosure describes a different activation/sedation profileThis is a laboratory behavioral distinction, not a clinical noninferiority or safety finding
Use. Ladasten anxiolytic-use disclosure; the patent provides a development source rather than independent clinical replication.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2175229C2 ↗ · 2001-10-27
- Earliest priority / filing
- 1999-12-22 / 1999-12-22
- Original applicant / assignee
- Научно-исследовательский институт фармакологии РАМН
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20228716 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Anxiolytic agent
Inventors: С.Б. Середенин; М.А. Яркова; Б.А. Бадыштов; тин Б.М. П; Б.М. Пятин; Н.И. Авдюнина; И.С. Морозов; Т.А. Воронина; Г.Г. Незнамов.
Related profiles: Bromantane
Peptide, preparation and pharmaceutical composition — US6248716B1
Reported findings
A preparation tested in the patent was associated with greater weight gain in a small animal-production comparison.
- Cattle weight gain
- 233.2 ± 2.4 kg treated versus 189.0 ± 2.7 kg control; 12 animals/groupStarting weights 72.3 ± 0.9 and 72.2 ± 1.1 kg; not human therapeutic benefit
- Daily gain
- 752 ± 17.3 g/day versus 610 ± 15.8 g/daySame cattle example; observation duration not independently entered
Use. Stress-related method claims involving defined peptide analogues in the sedatin/dermorphin research trail; sequence and terminal modifications limit transfer to other analogues.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- US6248716B1 ↗ · 2001-06-19
- Earliest priority / filing
- 1995-06-27 / 1999-05-27
- Original applicant / assignee
- Immunotech Developments Inc
- Indexed status
- Expired - Lifetime · checked 2026-11-06
- Patent family
- 27082120 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
Inventors: Vladislav I. Deigin; Elena P. Yarova.
Related profiles: Sedatin & dermorphin analogues
Pineal extracts: manufacturing and composition patent
Reported findings
The disclosed extract was associated with lower reported glucose measures over 12 weeks, without a verified product-specific Epithalamin match.
- Fasting glycemia
- Reported decreases of 15%, 22% and 29.4% from baselineWeeks 2, 4 and 12Treated group; baseline glucose values and modern allocation details not extracted
- Postprandial glycemia
- Reported decreases of 18.2%, 28% and 41%Weeks 2, 4 and 12Not absolute glucose concentrations
Platform context. The patent describes animal-pineal polypeptide complexes and proposed antioxidant or geroprotective uses, providing context for pineal-extract research.
A product-specific match to commercial Epithalamin was not established. This tissue-complex patent is not the defined AEDG Epitalon molecular patent, nor proof of human longevity.
- Publication
- RU2163129C1 ↗ · 2001-02-20
- Earliest priority / filing
- 2000-06-29 / 2000-06-29
- Original applicant / assignee
- Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20236906 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of preparing animal-origin complex of biologically-active polypeptides exhibiting antioxidant and geroprotection activities, pharmacological agent, and method for utilization thereof
Inventors: В.Х. Хавинсон; В.Г. Морозов; В.И. Семенова; О.В. Чайка; Г.А. Рыжак.
Related profiles: Epithalamin
Stemokin / Neogen: Ile-Glu-Trp and hematopoiesis
Reported findings
Some animal survival and immune-cell observations were favorable, without an established human treatment result.
- Tumor-model survival descriptions
- Lifetime reported approximately 4 days longer after peptide-related tumor-cell treatment and 15 days longer in a combination experimentDifferent experimental conditions; not patient survival
- Longer combination observation
- An approximately 20-day survival extension and survivors at 60 days described for another combinationDo not assign the combination effect to Ile-Glu-Trp alone
Use. The claimed peptide class includes Ile-Glu-Trp explicitly in a method directed at hematopoiesis.
The family contains multiple sequences; a peptide use claim is not proof of broad clinical immune restoration.
- Publication
- US6159940A ↗ · 2000-12-12
- Earliest priority / filing
- 1996-02-28 / 1999-06-28
- Original applicant / assignee
- Immunotech Developments Inc
- Indexed status
- Expired - Lifetime · checked 2026-11-06
- Patent family
- 26653668 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for modulating hemopoiesis
Inventors: Vladislav I. Deigin; Andrei M. Korotkov.
Related profiles: Stemokin / Neogen
Method of treating systemic lupus erythematosus
Reported findings
The patent reports lower anti-DNA antibodies and steroid changes in adjunctive Bemitil arms of the historical lupus program; unequal groups and follow-up prevent a causal efficacy estimate.
- Anti-DNA antibodies
- Reported within-group reductions in both Bemitil-containing arms
- Mean daily prednisolone, group 3
- 23.5 → 18.7 mg/day during observation
Use. Bemitil as an adjunct to glucocorticoids, with or without cyclophosphamide, in lupus. The patent and 1999 publication describe the same research program, not independent replications.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2157684C2 ↗ · 2000-10-20
- Earliest priority / filing
- 1997-12-22 / 1997-12-22
- Original applicant / assignee
- Научно-исследовательский институт фармакологии Российской академии медицинских наук
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20200796 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent for treatment of patients with systemic lupus erythematosis
Inventors: Т.А. Лисицына; А.Д. Дурнев; М.М. Иванова; С.Б. Середенин; В.А. Насонова.
Related profiles: Bemitil
Picamilon: pharmaceutical composition
Narrative findings; numerical extraction incomplete
The final example reports successful tableting and compliance with pharmaceutical requirements.
- Process example outcome
- At stated residual moisture of 3.9%, the material was described as tableting well and the resulting tablets as meeting requirementsManufacturing observation, not absorption or clinical benefit
- Clinical outcomes
- No controlled cognition, anxiety or neurological-treatment result supplied by these formulation examplesAbsence of clinical results is explicit
Formulation. The formulation identifies the sodium salt of N-nicotinoyl-GABA together with specified formulation components.
The composition patent is not evidence that every route or commercial formulation has the same clinical properties.
- Publication
- RU2149001C1 ↗ · 2000-05-20
- Earliest priority / filing
- 1999-09-09 / 1999-09-09
- Original applicant / assignee
- Открытое акционерное общество "Химикофармацевтический комбинат "Акрихин"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20224731 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Nootropic drug and method of its preparing
Inventors: И.И. Тюляев; В.А. Быков; Б.И. Демченко; А.П. Зуев; Н.И. Юрченко.
Related profiles: Picamilon
Vilon: Lys-Glu and reparative-process claims
Narrative findings; numerical extraction incomplete
The patent reports improvement during combined care, but the clinical series lack a clear concurrent untreated comparison.
- Salivary-stone postoperative course
- Edema/infiltration reportedly resolved 3–4 days after surgery, with cessation of purulent dischargeStone removal and other care prevent attribution to Vilon
- Inflammatory salivary-gland cases
- Pain/discharge reportedly stopped around days 4–5, with more salivation and reduced edemaClinical narrative; no numerical controlled effect estimate
Molecule. The document identifies the Lys-Glu dipeptide and proposed reparative applications.
The patent is a molecular and use source, not independent confirmation of clinical immune or longevity benefit.
- Publication
- RU2139085C1 ↗ · 1999-10-10
- Earliest priority / filing
- 1998-06-23 / 1998-06-23
- Original applicant / assignee
- Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20207251 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent stimulating reparative processes and method of its use
Inventors: В.Х. Хавинсон; В.Г. Морозов; В.В. Малинин; С.В. Серый.
RU2139085C1 · US6642201B1 · EP1089753B1 · JP4489946B2 · ATE245434T1 · AU776693B2 · CA2335362C · CH692477A5 · DE69909794T2 · IL140412A0 · WO1999066948A2
Related profiles: Vilon
Semax plus heparin: antithrombotic composition
Reported findings
The combination produced anticoagulant and antiplatelet effects in laboratory tests.
- Thrombin time
- 45.5 seconds with the complex versus 28.7 seconds with the heparin comparisonRat plasma clotting assay; longer is not an established clinical benefit
- Platelet aggregation
- Reported reduction from a 100% reference to 15%Experimental combination result; group denominator not supplied in the extracted narrative
Formulation. The claims concern an antithrombotic combination involving Semax and heparin.
A combined composition cannot demonstrate Semax-alone efficacy or justify unsupervised anticoagulant treatment.
- Publication
- RU2138269C1 ↗ · 1999-09-27
- Earliest priority / filing
- 1997-12-04 / 1997-12-04
- Original applicant / assignee
- Ашмарин Игорь Петрович; Ляпина Людмила Анисимовна; Пасторова Валентина Ефимовна; Каменский Андрей Александрович; Скворцова Вероника Игоревна; Мясоедов Николай Федорович
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20199624 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Antithrombosis agent
Inventors: И.П. Ашмарин; Л.А. Ляпина; В.Е. Пасторова; А.А. Каменский; В.И. Скворцова; Н.Ф. Мясоедов.
Related profiles: Semax
Polyprenols: immunomodulatory class-use patent
Narrative findings; numerical extraction incomplete
The direction of immune effects depended on genotype, exposure and assay; the patent does not support a uniformly stimulatory class effect.
- Context-dependent immune response
- Stimulation occurred under some conditions and suppression under othersNo single pooled clinical immune-effect size established
- Stress-associated findings
- Prevention of the reported humoral and macrophage-function impairment describedAnimal model; not a patient autoimmune outcome
Use. The disclosure concerns polyprenols as an immunomodulatory class.
A chemical-class patent does not authenticate every Ropren or POLYNCOR product, nor demonstrate each product's clinical effect.
- Publication
- RU2137479C1 ↗ · 1999-09-20
- Earliest priority / filing
- 1997-08-27 / 1997-08-27
- Original applicant / assignee
- Солагран Лимитед
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20196666 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Immunomodulating agent
Inventors: В.И. Рощин.
Related profiles: Polyprenols
Bestim: historical stereochemistry conflict
Narrative findings; numerical extraction incomplete
The patent reports restoration of lymphocyte measures in a selected case, with no controlled clinical effect estimate.
- Post-thymectomy case
- Total and T-lymphocyte measures described as returning to normal; patient discharged in satisfactory conditionSingle 18-year-old patient; image-based numerical table not transcribed
- Other selected case
- Colon-cancer-associated immunodeficiency example describedNo verified group response rate or independently extracted effect size
Identity unresolved. This historical patent calls its agent Bestim but claim 1 specifies gamma-L-Glu-L-Trp. The current research card describes gamma-D-Glu-L-Trp.
These stereoisomers cannot be treated as identical. The name alone does not establish continuity between the patent, later literature and current products.
- Publication
- RU2120298C1 ↗ · 1998-10-20
- Earliest priority / filing
- 1995-11-28 / 1995-11-28
- Original applicant / assignee
- Товарищество с ограниченной ответственностью "Верта"; Товарищество с ограниченной ответственностью "Цитокин"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20174019 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Immunostimulating agent and a preparation based on thereof
Inventors: О.А. Кауров; С.А. Кетлинский; А.А. Колобов; А.С. Симбирцев.
Related profiles: Bestim
Thymogen: L-Glu-L-Trp immune-deficiency use
Reported findings
The disclosure reports improved inflammatory/wound outcomes and immunological measures, but broad clinical percentage ranges are incompletely specified.
- Reported clinical response range
- 75.3–91.7% improvement or healing across described conditionsNo single verified denominator or common endpoint supplied
- Treatment duration
- Reported 20–30% shorter than control careCondition-specific sample sizes and uncertainty are not established from this summary
Use. The US claims concern purified L-Glu-L-Trp in a specified immune-deficiency-related use; the broader family traces earlier Thymogen development.
This alpha-linked L/L peptide differs from gamma-linked or D-amino-acid analogues. The granted method is narrower than all possible immune uses.
- Publication
- US5814611A ↗ · 1998-09-29
- Earliest priority / filing
- 1988-12-14 / 1995-06-07
- Original applicant / assignee
- Cytoven JV
- Indexed status
- Expired - Lifetime · checked 2026-11-06
- Patent family
- 27555548 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical for the therapy of immune deficiency conditions
Inventors: Vyacheslav Grigorievich Morozov; Vladimir Khatskelevich Khavinson.
Related profiles: Thymogen
Thymodepressin: D-amino-acid dipeptide claim
Reported findings
The patent reports context-dependent marrow recovery and improved survival in preclinical models.
- Cytopenia experiment
- Marrow karyocytes >2-fold, CFU-S-8 nearly 3-fold and CFU-S-12 >2-fold higher than cytostatic-only controlsDay 7 marrow examination24 mice total; 12 received the peptide
- Transplant-associated survival
- 45-day survival described as almost doubled versus control45 daysAbsolute survivor counts and schedule-specific denominators not transcribed
Molecule. Claim 3 identifies the D-glutamyl/D-tryptophan dipeptide associated with Thymodepressin within an immunosuppressive peptide program.
Linkage and stereochemistry distinguish this compound from Thymogen and Bestim; a patent does not demonstrate autoimmune efficacy.
- Publication
- US5736519A ↗ · 1998-04-07
- Earliest priority / filing
- 1995-06-07 / 1996-06-07
- Original applicant / assignee
- Individual
- Indexed status
- Expired - Lifetime · checked 2026-11-06
- Patent family
- 20168146 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
Inventors: Vladislav I. Deigin; Andrei Marxovich Korotkov.
US5736519A · EP0832900B1 · JP4082522B2 · CN1154653C · ATE260933T1 · AU724781B2 · BRPI9609235B8 · CA2222296C · CZ287816B6 · DE69631762T2 · DK0832900T3 · ES2217311T3 · HU228461B1 · LT4476B · LV12074B · PT832900E · RU2107692C1 · SK281825B6 · UA48974C2 · WO1996040740A1
Related profiles: Thymodepressin
Cortexin: brain-derived polypeptide complex
Reported findings
The patent reports several clinical improvement proportions, but endpoint definitions, treatment allocation and comparator denominators are incomplete.
- Cranial-trauma improvement
- 76% reported positive clinical effect versus 40% with conventional treatmentExact arm sizes and responder criteria are not sufficiently established
- Cerebral-palsy series
- Motor improvement 74%, mental-development improvement 65%, seizure-syndrome relief 41%89 children; overlapping outcomes, not mutually exclusive responder groups
Manufacturing. Claims describe a brain-tissue polypeptide preparation and its production, rather than a single defined synthetic peptide.
Historical preparation lineage does not authenticate every current product or establish disease-specific clinical benefit.
- Publication
- RU2104702C1 ↗ · 1998-02-20
- Earliest priority / filing
- 1996-10-16 / 1996-10-16
- Original applicant / assignee
- Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20186299 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of preparing the biologically active polypeptide complex normalizing brain functions from animal raw, pharmacological composition and its using
Inventors: В.Г. Морозов; В.Х. Хавинсон; О.В. Чайка; В.И. Семенова.
Related profiles: Cortexin
Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation
Experimental results unavailable in the accessed source
Experimental results could not be extracted from the accessed source; the later Chlodantane formulation patent is a separate disclosure.
- Original experimental outcomes
- Not available in the accessed bibliographic entryNo animal survival percentage or human performance effect is invented
Molecule. Historical chloro- and bromo-benzoylaminoadamantane disclosure in the Chlodantane development trail. It must not be conflated with Bromantane solely because bromine is mentioned.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- SU1646256A1 ↗ · 1996-06-10
- Earliest priority / filing
- 1989-07-13 / 1989-07-13
- Original applicant / assignee
- Научно-исследовательский институт фармакологии АМН СССР
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 60531599 · family publications are related filings, not independent studies.
Original title, inventors and related publications
2-(para-bromobenzoyl) or 2-(para-chlorobenzoyl)-aminoadamantanes increasing organism resistance to environment inhabitation extremal factor effect and showing immunostimulating activity
Inventors: И.С. Морозов; Н.Г. Арцимович; Н.В. Климова; Т.А. Фадеева; Н.М. Зайцева; Т.С. Галушина; Н.П. Быков; Б.М. Пятин; Н.И. Авдюнина; О.В. Щербакова; Г.В. Пушкарь; В.В. Каштанова; Т.Г. Хлопушина; Г.А. Кузнецова; И.А. Иванова; А.С. Лосев; Л.П. Ефимова; В.Г. Барчуков; С.А. Сергеева; Т.Д. Карпова; О.В. Агафонова; О.М. Краснова; С.Б. Середенин; Б.А. Бадыштов.
Related profiles: Chlodantane
Prostatilen: smooth-muscle use claims
Reported findings
Prostatilen-containing care had more reported favorable short-term prostate outcomes, with no verified randomization.
- Favorable conservative-treatment outcome
- 15/28 (54%) with Prostatilen versus 9/52 (17.3%) with symptomatic careAfter inpatient conservative carePatent-defined decision about unscheduled surgery
- Residual urine ≤100 mL subgroup
- 11/11 favorable outcomes versus 7/19 in controlsSmall, potentially selected subgroups
Use. The patent describes uses of Prostatilen involving prostate, bladder or venous smooth-muscle function.
The preparation is a tissue-derived complex; these claims do not establish equivalence to a defined synthetic prostate peptide.
- Publication
- RU2058780C1 ↗ · 1996-04-27
- Earliest priority / filing
- 1992-11-17 / 1992-11-17
- Original applicant / assignee
- Совместное русско-американское акционерное общество закрытого типа "Неофарм"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20132424 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent showing tonic action on the vein, bladder and prostate gland smooth muscle
Inventors: В.Х. Хавинсон; С.В. Серый; А.Л. Кожемякин; Р.И. Валеев.
Related profiles: Prostatilen
Para-chlorophenoxyacetic acid adamant-2-ylaminoethyl ester hydrochloride with claimed thermoprotective and psychostimulant activities
Experimental results unavailable in the accessed source
No experimental result can be responsibly transcribed from the accessed entry.
- Thermoprotection or stimulation outcome
- No extractable measured value in the accessed recordClaimed properties are not substituted for observed results
Molecule. Historical thermoprotective ester disclosure. The code-to-structure relationship must be retained rather than extended to unrelated adamantanes.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- SU1771186A1 ↗ · 1995-11-10
- Earliest priority / filing
- 1990-10-23 / 1990-10-23
- Original applicant / assignee
- Научно-исследовательский институт фармакологии АМН СССР
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 60533082 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Para-chlorophenoxyacetic acid adamant-2-ylaminoethyl ester hydrochloride showing thermoprotective and psychostimulating activities
Inventors: Н.В. Климова; Т.Д. Карпова; Ш. Караджаев; Н.П. Быков; Н.И. Авдюнина; Б.М. Пятин; И.С. Морозов; Г.В. Пушкарь; И.М. Зиновьева.
Related profiles: Adamantylaminoethyl chlorophenoxyacetate
Noopept: N-acylprolyl peptide derivatives
Reported findings
The disclosure reports anti-amnesic and withdrawal-related behavioral effects, plus reduced weight gain in one repeated-treatment experiment.
- Memory-related behavior
- Compound I reported to counter experimental memory disruption in passive-avoidance testsAnimal proxy; numerical table values not independently transcribed
- Repeated-treatment weight gain
- 12% versus 24% in controls, relative to starting body weight3 weeksA separate three-week rat observation; no human weight-loss inference
Molecule. The molecular family includes phenylacetylprolylglycine ethyl ester, the structure associated with Noopept.
A broad chemical class and patent examples do not substitute for clinical cognition or safety evidence.
- Publication
- US5439930A ↗ · 1995-08-08
- Earliest priority / filing
- 1992-04-14 / 1992-10-14
- Original applicant / assignee
- Russian-American Institute for New Drug Development
- Indexed status
- Expired - Lifetime · checked 2026-11-06
- Patent family
- 27128028 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
Inventors: Sergei B. Seredenin; Tatiana A. Voronina; Tatiana A. Gudasheva; Rita U. Ostrovskaya; Grigori G. Rozantsev; Alexander P. Skoldinov; Sergei S. Trophimov; James A. Halikas; Taisija L. Garibova.
Related profiles: Noopept
Bemitil for prevention of occupational hearing loss — patent RU2017483C1
Reported findings
The patent reports less hearing loss after one year in the Bemitil group.
- Hearing loss at one year
- 5/84 with Bemitil, 7/39 with conventional prophylaxis, 8/25 with placebo1 yearHearing loss of varying degree; allocation and masking unverified
- Illustrative worker: recovery time
- 4.5 hours without Bemitil versus 2 hours after a treatment cycleSingle-worker before/after example, not a cohort mean
Use. Historical Bemitil-related hearing-protection use disclosure; patent reports are not independent randomized clinical evidence.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2017483C1 ↗ · 1994-08-15
- Earliest priority / filing
- 1989-11-09 / 1989-11-09
- Original applicant / assignee
- Глазников Лев Александрович
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 21478461 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent for prophylaxis of professional hypoacusis
Inventors: Ю.К. Ревской; Л.А. Глазников; Б.Л. Макеев; В.Р. Гофман; М.А. Нестеров.
Related profiles: Bemitil
Thymalin lineage: thymus-derived preparation
Reported findings
The patent reports recovery and basic characteristics of the thymus-derived powder.
- Example product recovery
- 5.6 g of dry material reported from 500 g of starting thymus tissueManufacturing result; no clinical response denominator
- Product characteristics
- Polypeptide molecular-weight range 600–6,000 Da; pH of a 1% solution reported as 5.4An extract characterization, not proof of a single active sequence
Manufacturing. The patent describes preparation of a biologically active material from thymus glands.
This is an extract-process source, not proof that the extract is identical to a purified EW or EDP peptide or that all current products are equivalent.
- Publication
- US5070076A ↗ · 1991-12-03
- Earliest priority / filing
- 1985-07-02 / 1989-11-15
- Original applicant / assignee
- Leningradsky Gosudarstvenny Pedagogichesky Institut
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 27262725 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Thymus-gland preparation and method for producing same
Inventors: Vyacheslav G. Morozov; Vladimir K. Khavinson.
Related profiles: Thymalin
Kemantane: historical immunostimulatory-use disclosure
Reported findings
Case reports describe improved walking, ulcer healing and a lymphocyte marker, with no reliable treatment-rate estimate.
- Peripheral-vascular case
- Walking distance reportedly increased from 100–150 m to 500–700 mAfter a two-week course; one-year observation mentionedOne patient; concurrent care and standardized testing not established
- Ulcer case
- Foot ulcers reportedly healed during treatmentTwo weeks; favorable one-year observation describedAnother individual case, not a controlled ulcer-healing rate
Use. The Soviet publication describes Kemantane in an immunostimulatory application.
Historical disclosure is not a modern controlled clinical trial and does not establish autoimmune benefit.
- Publication
- SU1586711A1 ↗ · 1990-08-23
- Earliest priority / filing
- 1977-05-13 / 1977-05-13
- Original applicant / assignee
- Институт фармакологии АМН СССР
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20708410 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Immunostimulating agent "kemantan"
Inventors: Нинель Григорьевна Арцимович; Татьяна Александровна Фадеева; Юлия Анатольевна Шалыминова; Татьяна Евгеньевна Захарова; Ираида Андреевна Асташина; Ольга Васильевна Щербакова; Михаил Исаевич Шмарьян; Александр Борисович Вайншток; Нина Васильевна Климова; Лидия Николаевна Лаврова; Александр Петрович Сколдинов.
Related profiles: Kemantane
GHK-Cu: historical wound-healing patent
Reported findings
The patent reports smaller remaining wound size after copper-peptide treatment.
- Remaining wound size
- Reported 64.9% ±22.1 reduction versus contralateral controls in 14 wounds on 8 pigsDay 21This is remaining-area reduction, not the proportion of wounds completely healed
- Across animals
- Faster healing described in all 10 pigs studiedThe day-21 subset was smaller; wounds within an animal are not independent observations
Use. The granted disclosure concerns copper peptide complexes, including GHK-Cu, for wound-healing applications.
Historical patent examples are not an independent modern clinical trial; an expired index label is not a freedom-to-operate opinion.
- Publication
- US4760051A ↗ · 1988-07-26
- Earliest priority / filing
- 1985-01-24 / 1985-01-24
- Original applicant / assignee
- Individual
- Indexed status
- Expired - Lifetime · checked 2026-11-06
- Patent family
- 24788792 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Use of GHL-Cu as a wound-healing and anti-inflammatory agent
Inventors: Loren R. Pickart.
US4760051A · EP0189182B1 · JPH0674208B2 · ATE107310T1 · CA1286988C · DE3689909T2
Related profiles: GHK-Cu & GHK family
Piracetam: adjunctive cytostatic-treatment claim
Reported findings
The patent reports lower chemotherapy-associated toxicity signals, without establishing independent anticancer activity.
- Alopecia observation
- No alopecia in 32/47 patients receiving adjunctive PiracetamNo matched untreated comparator or prespecified alopecia assessment established
- Animal mortality
- Lower mortality with Piracetam during a cytostatic-toxicity experimentAbsolute survivor counts not supplied in the extracted narrative
Use. This historical use patent proposes piracetam alongside cytostatic treatment.
This is a later indication claim, not the original discovery patent, and does not demonstrate independent anticancer activity.
- Publication
- US4620973A ↗ · 1986-11-04
- Earliest priority / filing
- 1980-02-13 / 1985-06-14
- Original applicant / assignee
- Ciba Geigy Corp
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 4204090 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Use of nootropics
Inventors: Peter Truog.
US4620973A · JPS56128713A · BE887487A · CH657527A5 · DE3104703A1 · NL8100579A · ZA81936B
Related profiles: Piracetam
GHK: 2011 thermal-pain response patent
Reported findings
Copper-free GHK increased thermal-pain response latency in male mice compared with saline. This is preclinical patent evidence.
- Pain-response latency, lower GHK exposure
- 25.6 ± 1.9 seconds versus 18.0 ± 2.4 seconds with salineAcute thermal-pain test after pretreatmentCopper-free GHK 0.5 µg/kg; 10 mice/group; table reports M±m
- Pain-response latency, higher GHK exposure
- 23.6 ± 1.3 seconds versus 18.0 ± 2.4 seconds with salineSame acute comparisonCopper-free GHK 5 µg/kg; 10 mice/group; table reports M±m
Use. The single claim concerns copper-free Gly-His-Lys for thermal-pain analgesia, supported by a mouse comparison.
Unbound GHK is not GHK-Cu. A mouse pain-response result does not establish human analgesia or a new clinical indication.
- Publication
- RU2421235C1 ↗ · 2011-06-20
- Earliest priority / filing
- 2010-04-12 / 2010-04-12
- Original applicant / assignee
- Kursk State Medical University
- Indexed status
- IP Right Cessation — indexed historical event; official status unverified · checked 2026-11-07
- Patent family
- 44737905 · family publications are related filings, not independent studies.
Original title, inventors and related publications
APPLICATION OF PEPTIDE Gly-His-Lys FOR ANALGESIC EFFECT IN PAIN CAUSED BY THERMAL IRRITATION
Inventors: Максим Евгеньевич Долгинцев; Игорь Иванович Бобынцев; Михаил Юрьевич Смахтин; Алексей Анатольевич Крюков; Ольга Игоревна Иванова; Андрей Евгеньевич Белых.
Related profiles: GHK-Cu & GHK family
GHK plus Dalargin: 2011 bone-repair patent
Narrative findings; numerical extraction incomplete
The authors describe more advanced early bone repair with GHK plus Dalargin than with saline or either peptide alone. The evidence is qualitative radiography and histology.
- Combined treatment: radiographic appearance
- Fracture line described as barely visible with the combination; still visible but less pronounced with either peptide aloneDay 10Versus saline and single-peptide groups; no numerical radiographic score or uncertainty reported
- Combined treatment: histological appearance
- New bone formation and remodeling toward compact bone were described as more advanced in the combination groupDay 10Descriptive morphology; no quantitative histomorphometry or factorial interaction test
Related 2021 journal paper: neutrophil results → — a local-delivery rat study; its numerical results are not measurements from this patent.
Use. The claim combines unbound Gly-His-Lys with Dalargin for reparative osteogenesis; rat radiographs and histology support the disclosed rationale.
Combination findings must not be assigned to GHK-Cu, Dalargin alone or human fracture healing. No measured shortening of healing time or biomechanical strength was reported.
- Publication
- RU2429002C1 ↗ · 2011-09-20
- Earliest priority / filing
- 2010-09-13 / 2010-09-13
- Original applicant / assignee
- Kursk State Medical University
- Indexed status
- IP Right Cessation — indexed historical event; official status unverified · checked 2026-11-07
- Patent family
- 44758621 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of stimulating reparative osteogenesis
Inventors: Виктор Юрьевич Чердаков; Михаил Юрьевич Смахтин; Григорий Михайлович Дубровин; Игорь Иванович Бобынцев; Виктор Тарасович Дудка; Максим Евгеньевич Долгинцев; Алексей Анатольевич Крюков; Вадим Теймуразович Корошвили; Ирина Михайловна Соболева; Евгений Николаевич Кононец; Андрей Евгеньевич Белых; Ольга Игоревна Иванова.
RU2429002C1 · RU2589264C2 · RU2589265C2 · RU2593817C2 · RU2676659C1 · WO2021211006A1 · US5367053A · RU2193868C2 · RU2195311C2 · WO2004106491A2 · RU2295969C1
Related profiles: GHK-Cu & GHK family · Dalargin
GHK plus Thymogen: 2012 wound-healing patent
Reported findings
In the intradermal rat comparison, GHK plus Thymogen produced a higher wound-healing coefficient than saline or either peptide alone. No quantitative neutrophil endpoint was disclosed.
- Relative wound-healing coefficient: combination versus saline
- 0.56 ± 0.04 versus 0.29 ± 0.03Day 10Intradermal GHK plus Thymogen versus saline; 8 rats/group; M±m as printed
- Single-peptide comparators
- GHK 0.44 ± 0.04; Thymogen 0.41 ± 0.03Day 10Both differed from saline; the combination also differed from each single peptide
Use. The claim combines unbound Gly-His-Lys with Thymogen for skin-wound repair and neutrophil function. The grant publication is C2, not C1.
The numerical table concerns rat wound-area healing after intradermal treatment. It does not establish a measured neutrophil benefit, human wound efficacy or activity of GHK-Cu.
- Publication
- RU2452508C2 ↗ · 2012-06-10
- Earliest priority / filing
- 2010-09-13 / 2010-09-13
- Original applicant / assignee
- Kursk State Medical University
- Indexed status
- IP Right Cessation — indexed historical event; official status unverified · checked 2026-11-07
- Patent family
- 46029806 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for stimulating wound healing and functional activity of neutrophils
Inventors: Виктор Юрьевич Чердаков; Михаил Юрьевич Смахтин; Григорий Михайлович Дубровин; Игорь Иванович Бобынцев; Максим Евгеньевич Долгинцев; Алексей Анатольевич Крюков; Евгений Николаевич Кононец; Ирина Михайловна Соболева; Яна Вячеславовна Кремзукова; Андрей Евгеньевич Белых; Ольга Игоревна Иванова.
Related profiles: GHK-Cu & GHK family · Thymogen
Unbound GHK for liver regeneration
Narrative findings; numerical extraction incomplete
Mitotic activity increased from 1.5 µg/kg without further increases at higher doses. Higher doses produced more dystrophic changes. Patent claim and description disagree on dose units.
- GHK dose series and mitotic activity
- Five daily intraperitoneal injections: 0.5 µg/kg had no substantial activity; 1.5 µg/kg increased mitotic index; 50, 150 and 450 µg/kg did not further increase itHistology the day after the fifth injectionHealthy Wistar rats, 8–10 per group; numerical figure values and uncertainty not extracted
- Higher-dose tissue changes
- Dystrophic changes described at 50, 150 and 450 µg/kg, especially at 450 µg/kgNo dystrophic changes described at 1.5 µg/kg in the healthy-animal example; not proof of long-term safety
Use. Experimental use of unbound Gly-His-Lys to stimulate physiological and reparative hepatocyte proliferation. Description: five daily intraperitoneal injections in rats.
Animal patent disclosure, not a human trial or GHK-Cu administration study. Description uses µg/kg while the claim prints µg/g; this 1,000-fold discrepancy is unresolved. Related journal and thesis reports may share experiments.
- Publication
- RU2214269C1 ↗ · 2003-10-20
- Earliest priority / filing
- 2002-03-07 / 2002-03-07
- Original applicant / assignee
- Kursk State Medical University
- Indexed status
- Index reports lapse for nonpayment; official status not independently verified · checked 2026-11-08
- Patent family
- 31988876 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Способ стимуляции физиологической и репаративной регенерации печени
Inventors: M. Yu. Smakhtin; I. A. Shveinov; A. A. Konoplya; L. A. Sever’yanova; I. I. Bobyntsev.
Related profiles: GHK-Cu & GHK family
Immune-profile-directed peptide selection with psoriasis photochemotherapy
Reported findings
The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.
- Alternative-treatment examples
- Dalargin case B cells 10%→20%; Thymalin case 32%→13%; T-activin case 28.6%→14%One selected patient per peptide, with photochemotherapy; changes are not comparative treatment effects
- Dalargin case: immune measures
- T-suppressor index 9%→25%; T-helper index 71%→55%Example 2; B cells 10%→20%; historical subset methods are not modern Treg measurements
Use. Selects Dalargin, Thymalin or T-activin as alternatives according to historical lymphocyte profiles, alongside photochemotherapy. Not a claim to simultaneous Thymalin–Dalargin administration.
Selected case reports with photochemotherapy and historical immune assays; no controlled pair trial or isolated peptide effect. Russian dose/frequency statements are distinguished from mistranslated English text.
- Publication
- SU1674849A1 ↗ · 1991-09-07
- Earliest priority / filing
- 1989-03-20 / 1989-03-20
- Original applicant / assignee
- Irkutsk State Medical Institute
- Indexed status
- Current legal status not established from this indexed record; official register not reviewed · checked 2026-11-08
- Patent family
- 21434935 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Способ лечения псориаза
Inventors: I. O. Malova; R. G. Skvortsova; N. P. Kuznetsova.
RU2503459C2: paired brain peptide fractions in cycling and swimming
Reported findings
4.5±0.2 to 8.4±0.2 min with A + B; saline 4.3±0.3 to 4.6±0.5 min. Applicant-reported athlete data.
- Cyclists · maximal-speed duration
- 4.5±0.2 to 8.4±0.2 min with A + B; saline 4.3±0.3 to 4.6±0.5 minDays 1 to 21; n=6 per arm. Day 21 A-only and B-only: 6.8±0.2 and 6.7±0.1 min.
- Cyclists · submaximal distance
- 8500±150 to 15500±120 m with A + B; saline 6300±120 to 7100±100 mDays 1 to 21; approximately 60% of maximal speed.
Formulation. Claims a 2–5 kDa limbic and associated region fraction paired with a 0.5–0.9 kDa midbrain periaqueductal-gray fraction, approximately 2:1 to 3:1 A:B by mass.
Different preparation from cortex-derived PPK-V. Athlete observations are applicant-reported and overlap the companion filing; the claimed synergy is unconfirmed.
- Publication
- RU2503459C2 ↗ · 2014-01-10
- Earliest priority / filing
- 2012-03-22 / 2012-03-22
- Original applicant / assignee
- N. N. Karkishchenko; V. N. Karkishchenko
- Indexed status
- Not shown; official status unverified · checked 2026-11-08
- Patent family
- 49554878 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Средство для стимуляции работы в экстремальных условиях, способ его получения и его применения
Inventors: N. N. Karkishchenko; V. N. Karkishchenko.
Related profiles: Brain peptide fractions A and B
RU2496504C1: midbrain peptide fraction in cycling and swimming
Reported findings
4.2±0.1 to 6.7±0.1 min with B; saline 4.3±0.3 to 4.6±0.5 min. Applicant-reported athlete data.
- Cyclists · maximal-speed duration
- 4.2±0.1 to 6.7±0.1 min with B; saline 4.3±0.3 to 4.6±0.5 minDays 1 to 21; n=6 per arm.
- Cyclists · submaximal distance
- 7200±130 to 11600±100 m with B; saline 6300±120 to 7100±100 mDays 1 to 21.
Formulation. Claims a 500–900 Da peptide fraction derived from midbrain periaqueductal gray of cattle or pigs, with extraction and administration claims.
Corresponds to the Fraction B preparation in the companion filing; overlapping data are not independent confirmation.
- Publication
- RU2496504C1 ↗ · 2013-10-27
- Earliest priority / filing
- 2012-03-22 / 2012-03-22
- Original applicant / assignee
- Scientific Center for Biomedical Technologies, Russian Academy of Medical Sciences
- Indexed status
- Not shown; official status unverified · checked 2026-11-08
- Patent family
- 49253700 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Средство для стимуляции работы в экстремальных условиях, способ его получения и его применения
Inventors: N. N. Karkishchenko; V. N. Karkishchenko; S. L. Lyublinskiy; A. A. Stepanov.
Related profiles: Brain peptide fractions A and B
RU2049472C1: Cerebrolysat manufacturing from bovine brain tissue
Reported findings
Bovine brain homogenate enzymatic hydrolysis, ethanol precipitation, microfiltration and 5–15 kDa nominal ultrafiltration cutoff.
- Example 1 · process
- 10 kDa cutoff; 200 mL final volumeStarting example used 1 kg brain material and serine endoprotease.
- Example 2 · process
- 15 kDa cutoff; applicant reported matching amino-acid compositionThis is the composition comparison stated in the disclosure.
Manufacturing. Bovine brain homogenate enzymatic hydrolysis, ethanol precipitation, microfiltration and 5–15 kDa nominal ultrafiltration cutoff.
A membrane cutoff is a process parameter. It does not establish the peptide-size distribution or an identity match to PPK-V.
- Publication
- RU2049472C1 ↗ · 1995-12-10
- Earliest priority / filing
- 1992-12-21 / 1992-12-21
- Original applicant / assignee
- Not established from accessed metadata
- Indexed status
- Not shown; official status unverified · checked 2026-11-09
- Patent family
- 20133945 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Способ получения гидролизата мозговой ткани «церебролизат»
Inventors: A. V. Karyakin; G. S. Vasilyev; V. G. Yusupov; V. N. Melnikov; V. F. Kulagin.
Related profiles: Cerebrolysat
RU2709503C1: Selank in acute cold-water hypothermia models
Reported findings
Applicant claims use of Selank for resistance to acute cooling, with separate rat swimming and survival examples.
- Free swimming · Example 1
- 23% longer active swimming than saline10 rats per arm at 9°C; reported p<0.05.
- Post-exposure arm · Example 2
- 40% survived the subsequent observation periodOnly 25% of saline controls survived the first hour and all died by day 2. Patent reports a 3.2-fold first-hour survival comparison.
Use. Applicant claims use of Selank for resistance to acute cooling, with separate rat swimming and survival examples.
Animal patent experiments. Human treatment of hypothermia is outside the evidence.
- Publication
- RU2709503C1 ↗ · 2019-12-18
- Earliest priority / filing
- 2019-05-23 / 2019-05-23
- Original applicant / assignee
- Not established from accessed metadata
- Indexed status
- Not shown; official status unverified · checked 2026-11-09
- Patent family
- 69006996 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Применение пептида Thr-Lys-Pro-Arg-Pro-Gly-Pro (селанк) для повышения резистентности организма к острой гипотермии
Inventors: L. A. Andreeva; V. P. Vdovichenko; E. A. Nemersky; A. Yu. Petrovskaya; A. K. Petrovsky; N. A. Smirnov; V. N. Fedorov; T. B. Fedorova.
Related profiles: Selank
RU2469730C2: Cortexin in a multi-stage biathlon protocol
Reported findings
Cortexin as one stage of a multi-part athlete protocol with preparatory psychotherapy and follow-up.
- Course time and shooting
- Distance time −5.6%; shooting misses −26%Applicant-reported changes. Absolute group means and reliable per-arm counts are missing from the checked text.
- Final race result
- Reported improvement of 6%Methods do not establish a blinded causal effect.
Use. Cortexin as one stage of a multi-part athlete protocol with preparatory psychotherapy and follow-up.
The biathlon example may overlap with 2011–2012 reporting. Allocation, exact cohort match and independent replication are unresolved.
- Publication
- RU2469730C2 ↗ · 2012-12-20
- Earliest priority / filing
- 2011-03-23 / 2011-03-23
- Original applicant / assignee
- Not established from accessed metadata
- Indexed status
- Not shown; official status unverified · checked 2026-11-09
- Patent family
- 47078124 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Способ улучшения психоэмоционального состояния организма спортсменов
Inventors: V. A. Bukharin; V. P. Ganapolsky; A. V. Taymazov; D. S. Tsvetkov.
Related profiles: Cortexin
RU2801151C1: Bovine brain protein–polypeptide hydrolysate process
Reported findings
Bovine brain hydrolysate manufacturing process with analytical and yeast-growth checks.
- Ninety-day rat tolerability series
- 160 rats, four arms of 40. No adverse change in measured behavior, blood biochemistry or organ pathology was described.Daily intramuscular 1.5, 15 or 150 mg/kg versus water control. Applicant-reported toxicology; underlying tables were not recovered.
- Reported final protein–polypeptide concentration
- 1.0–2.0 mg/mLPreparation concentration, not a human dose.
Manufacturing. Bovine brain hydrolysate manufacturing process with analytical and yeast-growth checks.
A distinct patent-defined preparation. No verified equivalence to Cerebrolysat, Cortexin, PPC-M or PPK-V.
- Publication
- RU2801151C1 ↗ · 2023-08-02
- Earliest priority / filing
- 2022-08-15 / 2022-08-15
- Original applicant / assignee
- Not established from accessed metadata
- Indexed status
- Not shown; official status unverified · checked 2026-11-09
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Способ получения биологически активного белково-полипептидного гидролизата из тканей мозга
Inventors: N. V. Fedota; A. N. Shulunova; A. N. Kvochko.
Related profiles: Bovine brain hydrolysate RU2801151
RU2485132C2: Embryonic neural protein–polypeptide complex
Reported findings
Ungulate embryonic neural-tissue protein–polypeptide complex and a composition containing nucleotide material.
- Example 11 · rat survival after bilateral carotid ligation
- 34/36 after injected complex versus 9/24 untreated controlsIntraperitoneal 0.2 mg/kg at one and five hours, as described. Applicant reports p≤0.01 versus control.
- Example 11 · intranasal count conflict
- Narrative 30/36 survivors; Table 1 prints 32/36 with 6 deaths and 83%The nasal arm cannot be reconciled from the filing. Timing and exposure also differ from the injected arm.
Formulation. Ungulate embryonic neural-tissue protein–polypeptide complex and a composition containing nucleotide material.
Separately manufactured patent-defined product. Cortexin and Cerebrolysin are background comparators, and the filing does not establish equivalence to PPK-V.
- Publication
- RU2485132C2 ↗ · 2013-06-20
- Earliest priority / filing
- 2011-05-30 / 2011-05-30
- Original applicant / assignee
- Not established from accessed metadata
- Indexed status
- Not shown; official status unverified · checked 2026-11-09
- Patent family
- 47259597 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Белково-полипептидный комплекс с антигипоксическим и репаративным действием, способ его получения и фармацевтическая композиция
Inventors: A. B. Nazarenko; M. A. Sokolov.
Related profiles: Embryonic neural protein–polypeptide complex
RU2521324C1: Antitox and SportAktiv-2 cryopowders in rowers
Reported findings
A paired food-concentrate intervention using plant and rabbit-meat cryopowders in adolescent rowers.
- Dominant hand strength
- +9.0% in the active groupAuthors report no increase in the comparison group; half of active participants improved.
- Cholesterol
- Total −10.8%; LDL −30.9% in active groupApplicant comparisons, not confirmed in an independent study.
Formulation. A paired food-concentrate intervention using plant and rabbit-meat cryopowders in adolescent rowers.
The patent tests the paired nutritional intervention. The study cannot assign findings to either powder alone or to a purified peptide.
- Publication
- RU2521324C1 ↗ · 2014-06-27
- Earliest priority / filing
- 2013-03-14 / 2013-03-14
- Original applicant / assignee
- Not established from accessed metadata
- Indexed status
- Not shown; official status unverified · checked 2026-11-09
- Patent family
- 51218218 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Способ коррекции морфофункционального состояния спортсменов
Inventors: R. S. Rakhmanov; N. I. Belousko; L. A. Strakhova.
Related profiles: Antitox + SportAktiv-2
Source-check dates: 6–7 November 2026; individual records retain their dates. Evidence standards · Send a patent or identity correction